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  Stroke is the number one cause of adult disability in the United States and the 
third leading cause of death in the United States, Europe, and China.  It is estimated 5% 
to 15% of all strokes are caused by ruptured intracranial aneurysms.  In 2010, the 
National Stroke Association estimated the direct and indirect cost of strokes was $73.3 
billion.     
 The most common method for treating intracranial aneurysms is with platinum 
coils that are deployed to pack the aneurysm and block blood flow and prevent rupture.  
However, coil compaction and re-bleeding are two limitations with the coils because 
they have limited space filling capacity.  Dr. Duncan Maitland has proposed a 
neurovascular embolization device (NED) be made out of shape memory polymer foam 
(SMP).  The SMP device can be compressed down into a compact size for delivery via a 
catheter.  Once in place, the device can be stimulated to regain its primary shape and 
expand up to 70x for superior occlusion of aneurysms. 
 Design research is necessary to generate performance specifications for the NED 
that can assess the quality of prototypes.  Customer needs are generated from interviews, 
activity diagrams, and market research.  Functional models define the function and 
various sub-functions of the NED.  Benchmarking highlights technology trends.  A 
House of Quality matrix maps the customer needs to the engineering requirements.  A 
failure modes and effects analysis emphasizes possible design deficiencies as a way of 
mitigating future risk.  Performance specifications for the SMP foam are defined and can 
be used to establish a quality control program.  Purification methods are suggested for 
the chemicals used in the synthesis of the SMP foam.  Purification of the chemicals can 
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1. INTRODUCTION: THE IMPORTANCE OF RESEARCH 
 
 The need for neurovascular embolization devices (NED) stems from the fact that 
untreated intracranial aneurysms can result in devastating consequences.  Approximately 
3 out of 4 patients with ruptured aneurysms will die or become neurologically 
incapacitated.  Ruptured aneurysms cause strokes by bleeding in between the brain and 
the subarachnoid space, leading to subarachnoid hemorrhage.  Approximately 795,000 
people each year have a stroke, killing about 137,000 people.
1
  These startling statistics 
have led to the development of multiple products attempting to treat intracranial 
aneurysms.     
 After their approval in 1995 by the FDA, Guglielmi Detachable Coils (GDC) 
revolutionized the way intracranial aneurysms could be treated.  A craniotomy along 
with surgical ligation was no longer the only option.  Over the last 15 years, 
approximately 200,000 patients have been treated with the coiling method with positive 
results.   However, there are limitations with the current market products that need to be 
addressed.  Coil compaction and rebleeding are the two most prominent.  These 
consequences result because the current market products have limited space filling 
capacity.  The right combination of materials and design has not yet been developed and 
is limiting complete aneurysm occlusion.     
 As a solution to these problems, a device will be designed out of a urethane-
based shape memory polymer (SMP).  This polymeric smart material can remember a 
primary shape and return from a temporarily deformed shape back into the primary 
shape once stimulated by an external stimulus. The trigger (actuation) can be heat, light, 
or chemically driven.
2
  The shape memory characteristic gives the device the ability to 
be compressed down into a compact size for delivery via a catheter.  Once in place the 










2.1 Characteristics of Intracranial Aneurysms 
 
In a normal artery wall there are 3 layers.
3
  The innermost endothelial layer is the 
intima which consists of endothelial cells and is supported by an internal elastic lamina.  
The media is the intermediate layer and is composed of smooth muscle.  Finally, the 
outer layer is the adventitia which is made up of connective tissue.  The cause or process 
by which intracranial aneurysms form, grow, and rupture is not very well understood.
4
  
Based on examination, though, a typical aneurysm has a severely fragmented or no 
elastic lamina and a very thin or no media.
5
  These characteristics along with 
hemodynamic shear stresses on the wall of intracranial arteries lead to vessel wall 
fatigue and the formation of an aneurysm.
4
  Risk factors which contribute to an increased 
prevalence include family history and environmental factors like smoking and 
hypertension.  
The prevalence of intracranial aneurysms in the adult population without specific 
risk factors is estimated to be approximately 2.3%.
6
  It has been estimated 1 million to 
12 million Americans have them.
5
  The actual number of aneurysms is higher, though, 
considering 20% to 30% of patients have two or three in number.
5
   
It is, therefore, important to understand the geometry and the risks associated 
with the size and location of an intracranial aneurysm.
7
  The possible treatment options 
will depend on the shape, size, and location of the aneurysm.  The shape of intracranial 
aneurysms can be classified as saccular, fusiform, or dissecting.  Saccular aneurysms 
account for 90% and are rounded and berry-shaped.
8
  Fusiform aneurysms take on 
bizarre, spindle-shaped geometries that vary both in diameter and length.  Intracranial 
dissecting aneurysms are rare, but are caused by blood accumulating within the arterial 
wall because of a rip in the intima.
3
   
 Two important characteristics are used to describe the size of an aneurysm.  One 





categories.  The diameter of the fundus for a small aneurysm is less than 5 mm, for a 
medium aneurysm it is 6-15 mm, for a large aneurysm it is 16-24 mm, and for a giant 
aneurysm it is any that are larger than 25 mm.  The larger the aneurysm, the more likely 
it will rupture.  However, most ruptured aneurysms are small to medium in size due to 
the fact that 90% have a fundus defined as less than 1 cm in diameter.
9
  The second 
important characteristic is the size of the neck.  Wide-necked aneurysms are considered 
those with a neck diameter greater than 4 mm, a dome-to-neck diameter ratio less than 2 
to 1, or a neck diameter greater than one half the diameter of the parent vessel.
10
  
 Location is also an issue that can hinder successful occlusion.  Bifurcations of 
major arteries are a common location for aneurysms.  The exact location of the aneurysm 
varies but approximately 86.5% arise on the anterior circulation.  Locations within the 
anterior circulation include the anterior communicating artery (30%), the internal carotid 
artery at the posterior communicating artery origin (25%), the middle cerebral artery 
bifurcation (20%), the internal carotid artery (7.5%), and the 
pericallosal/callosomarginal artery bifurcation (4%).
3
  Aneurysms also arise on the 
posterior circulation, with the basilar artery bifurcation accounting for 7%, and an 
additional 3% on the posterior inferior cerebellar artery.
3
    
 
2.2 Risks of Intracranial Aneurysm 
 
 Stroke is the number one cause of adult disability in the United States and the 
third leading cause of death in the United States, Europe, and China.
11,12
  It is estimated 
5% to 15% of all strokes are caused by ruptured intracranial aneurysms.
4
  For those 
people fortunate enough to survive a stroke, long-term care can inflict a considerable 
emotional, mental, and financial burden.  In 2010, the National Stroke Association 
estimated the direct and indirect cost of strokes was $73.3 billion.     
 One of the causes that accounts for 5% of strokes is subarachnoid hemorrhage 
which is a devastating condition.
9
  Intracranial aneurysms are the cause of 85% of all 
subarachnoid hemorrhages.
13





from a ruptured intracranial aneurysm is 10 per 100,000 people per year.
5
  These results 
lead to approximately 27,000 new cases each year.
4
  The glaring dangers associated with 
subarachnoid hemorrhage cannot be overstated.  About 10% to 15% of the people who 
suffer a subarachnoid hemorrhage die before reaching the hospital and within 30 days 
the fatality rate increases to 50%.
14
  An estimated 20% to 35% of the survivors will have 
moderate to severe brain damage, even after treatment.
15
  After 6 months, untreated 
ruptured aneurysms have a morbidity of 48% to 78% and a mortality of 60% as a result 
of rerupture.
10
  These statistics and associated complications reveal the importance for 
treatment of intracranial aneurysms ideally before they rupture. 
 
2.2 History of Treatment 
 
 Considering the danger an intracranial aneurysm poses to a patient’s survival, it 
is imperative to have safe and effective treatment options.  Currently the two available 
treatment options are surgical clipping via a craniotomy or an endovascular approach.  
The first surgical treatment using a vascular clip was performed in 1936.
5
  Morbidity 
was initially high from aneurysm ligation and clipping, but advances in neurosurgical 
techniques over the decades allowed surgery to remain the predominant treatment 
option.
16
  Still though, surgical clipping is a highly invasive procedure.  A craniotomy 
must be performed where a bone flap is temporarily removed from the skull.  The brain 
is then retracted to locate the aneurysm.  Once located, one small titanium clip is placed 
across the neck of the aneurysm to block blood flow from entering.   
 Due to the necessity of cutting open the skull, negative results stemming from 
surgery include extended hospital stays and high hospital costs.
17
  As a remedy to these 
problems there were attempts at minimally-invasive endovascular techniques using 
detachable balloons, iron particles, and platinum coils.  Problems arose, though, due to 
balloon deflation, migration of particles, and aneurysm rupture.
17
  It was not until the 
1995 approval of GDCs that an endovascular technique began to be widely adopted.  





 Even as coiling methods have improved there are still two main failure modes for 
coil embolization; the inability to completely occlude the aneurysm and coil compaction 
which over time leads to recanalization.  Due to mounting criticism about the bare 
platinum coils being insufficient, development began on bioactive and coated coils.  
These advanced coils can be separated into two broad categories as polyglycolic-
polylactic acid (PGPLA)-containing coils and hydrogel-coated coils.  The PGPLA-
containing coils are meant to initiate an inflammatory response when implanted in the 
aneurysm that generates an assemblage of thrombus and eventually fibrosis.  They are 
supposed to elicit a faster neointimal overgrowth at the neck of the aneurysm.  The 
hydrogel-coated coils absorb water and expand once introduced into the bloodstream.  
The hydrocoils expand to five times the volume of standard platinum coils.
18
 
 The best packing densities that have been observed in glass and silicone 
aneurysm models with current embolization coils range from 30% to 40%.  The density 
drops to 20% to 30% in clinical human aneurysm treatments.
18
  The random placement 
of coils within the aneurysm and the propensity for coils to split the aneurysm into 
separate partitions leaves the majority, 70% to 80%, of the aneurysm not filled with 
metal.
18
  A limit in the packing density has ramifications which can result in 
recanalization of the aneurysm.  Studies have shown treated aneurysms with 
recanalization rates of 33.6%.  The recanalization rates were higher, 50.6% and 52.3%, 
for large and wide-necked aneurysms, respectively.
19
   
 Even with a robust evolution of various techniques, the endovascular approach is 
ultimately still falling short of complete occlusion of the aneurysm.  This limitation 
opens up an opportunity for research into advanced materials and an improvement in the 










2.4 Solution for Improvement – Shape Memory Polymer 
 
Shape Memory Polymers (SMP) are a class of polymeric materials that have the 
ability to change their shape upon application of an external stimulus.
20
  The polymer is 
first processed into its permanent shape.  The polymer is then deformed into a temporary 
shape, which is called the programming stage.
21
  Programming in the Biomedical Device 
Laboratory consists of heating the SMP above the glass transition temperature, Tg, 
deforming it into a cylindrical shape, and then cooling the SMP.  The permanent shape is 
stored into memory while the sample holds the temporary shape.  Subsequent heating of 
the sample above the Tg induces the shape memory effect and the sample returns to its 
permanent shape.
21
  The trigger (actuation) can be heat, light, or chemically driven.   
There are many advantages that make SMP a suitable material for the treatment 
of intracranial aneurysms.  They have a high capacity for elastic deformation, easy 
processing, potentially lower manufacturing cost, and versatility in designing complex 
geometries.
2
  These materials have also been found to be biocompatible.  Cytoxicity and 
mutagenicity tests have shown excellent results.
22
  Significant potential for medical 
devices has recently been demonstrated.
21,23,24
  The shape memory characteristic gives 
the material the ability to be compressed down into a compact size for delivery via a 
catheter.  Once in place, the device can be induced to regain its complex, primary shape.  
















3. RESEARCH AND DEVELOPMENT OF NED SYSTEM 
 
3.1 Brief History of Medical Device Regulations in the U.S. 
  
 In the United States, medical device regulation was enacted in 1976 when the 
Medical Device Amendments to the Federal Food, Drug, and Cosmetic Act of 1938 was 
signed into law by Congress.
26
  Good Manufacturing Practices (GMP) at that time was a 
quality control program for the control of manufacturing, packaging, storage, 
distribution, and installation of medical devices.
27
  The Safe Medical Devices Act of 
1990 then gave the FDA authority to add “preproduction design validation controls” to 
the GMP regulations, which were then incorporated into the Quality System Regulation 
(QSR)
28
  The QSR, however, did not go into effect until 1997 and was not enforced until 
1998.  This mandate was put into place after an FDA study showed that over 40% of all 
quality problems resulting in recalls were attributable to preproduction-related 
problems.
29
  It is now required by the FDA for medical device manufacturers to 
incorporate design controls while developing their products.  The QSR is in Part 820 of 
Title 21 of the Code of Federal Regulations (CFR).
30
   
 In 1996, the Medical Device Reporting (MDR) regulation went into effect for the 
purpose of providing the FDA a way to receive information about significant adverse 
events with medical devices.
29
  These various regulations now mean the medical device 
manufacturer is responsible for the entire life cycle of a medical device; from design, to 
manufacturing, to post-market surveillance.  The regulations require that the Biomedical 
Device Laboratory have a quality system for the design and manufacture of the NED 










3.2 Regulatory Guidelines for the NED System 
 
 Medical devices are organized into classes based on the associated degree of risk 
and intended use.
28
  Class I are simple, low risk devices, while Class II are higher risk 
and more complex devices that are not life sustaining. Class III devices have the highest 
risk since they either support human life, prevent impairment of human health, or present 
an unreasonable risk of illness or injury.      
 In 1979, NEDs were initially classified into Class III due to concerns about tissue 
toxicity and tissue infarction.  However, in 2004 they were down-classified to Class II 
with the stipulation that medical device manufacturers follow the FDA guidance 
document, “Class II Special Controls Guidance Document: Vascular and Neurovascular 
Embolization Devices”. 
 The FDA product code assigned to NEDs is ‘HCG’ ( Table 1).  With this 
information, predicate devices can be researched for benchmarking purposes and the 
indication for use can be defined.  The NED being developed in the Biomedical Device 
Laboratory is intended for the endovascular embolization of intracranial aneurysms.  
This indication will set the foundation for the future direction of the development plan.   
 
Table 1. FDA Classification for the NED System  
FDA Classification for the Neurovascular Embolization Device (NED) 
Classification 





Product Code HCG 
Examples 
Embolization coils 
Polyvinyl alcohol particles 
Nonresorbable particles 
Device Class  2 
Submission Type  510(k) 
GMP Exempt? No 
Identification 
A neurovascular embolization device is an intravascular implant intended to permanently 
occlude blood flow to cerebral aneurysms and cerebral arteriovenous malformations. This 
does not include cyanoacrylates and other embolic agents, which act by polymerization or 
precipitation. Embolization devices used in other vascular applications are also not included 
in this classification, see 21 CFR 870.3300. 
Guidance Document 
The special control for the device is the FDA guidance document entitled “Class II Special 






3.3 NED System Deployment and Architecture 
 
 The NED system comprises three subsystems: the NED, the delivery pusher, and 
the detachment mechanism (P&D).  The NED is used to occlude intracranial aneurysms.  
The delivery pusher is used to guide the NED to the aneurysm site.  The detachment 
mechanism is then used to release the NED into the aneurysm.   
 Additional components required during the endovascular procedure include: 
digital subtraction fluoroscope, femoral sheath, guidewire, 5-8 Fr guiding catheter, 
microcatheter, two rotating hemostatic valves (RHV), three-way stopcock, one-way 
stopcock, 20-22 gauge sterile needle (Fig. 1).  Three continuous heparinized saline flush 
setups with pressure bags are also needed; one for the femoral sheath, one for the 
guiding catheter, and one for the microcatheter. 
 A typical endovascular procedure occurs in a catheterization laboratory under 
general anesthesia.  A biplanar fluoroscopic system is used to visualize in vivo the proper 
positioning and placement of the radiopaque coils.  To begin the procedure, a 5 to 6 
French sheath is inserted into a femoral artery puncture.  A guiding catheter is then 
introduced into the proximal parent artery, normally the left internal carotid artery.  At 
this point the catheter is continuously flushed with saline.  A preliminary angiography is 
performed to assess the size of the aneurysm and the tortuous vessel pathway leading to 
it.  A microguidewire is then navigated to the base of the aneurysm.  Once in place, a 
microcatheter is passed over the microguidewire.  A coil is loaded into the microcatheter 
and pushed through to the distal end.  The first coil implanted serves as the “framing 
coil” which shields the neck and follows the shape of the aneurysm wall.  Subsequent 
smaller sized coils are then placed to slowly occlude the aneurysm.  An angiography is 
performed to check the occlusion rate and is considered successful if no contrast material 
enters the aneurysm.  The procedure is completed once the guide wires and catheters 















3.4 Current NED Prototypes 
  
 As a solution to the shortcomings of current market products, the Biomedical 
Device Lab is developing a NED made from SMP foam.    
 One design concept fabricated by Wonjun Hwang consists of a SMP foam-only 
device that is crimped around a resistive heating element (Fig. 2).  The resistive heating 
element is used to deliver and actuate the foam.  Once the foam is actuated, the resistive 
heating element is removed.  A current limitation with this embodiment, is fabricating 
the whole system to a small enough outer diameter to facilitate easy placement into a 
microcatheter.     
  
 
Figure 2. SMP Foam-Only Device with Resistive Heating Element 
  
 A design concept fabricated by Tony Boyle consists of a SMP foam segment 
crimped over a shape memory alloy (SMA) wire backbone (Fig. 3).  The SMP foam-
over-wire embodiment utilizes passive actuation.  The foam softens during actuation 







Figure 3. SMP Foam-Over-Wire Device 
 
 A concept for the detachment mechanism consists of a ball-and-socket (Fig. 4).  
The ball is attached to the NED and when the socket is pushed out of the microcatheter, 
the NED is detached.   
 
 
Figure 4. Ball-and-Socket Detachment Mechanism 
 
   The research for this thesis complements the current prototyping research being 
done in the Biomedical Device Laboratory.  An attempt was made to strike a balance 
between remaining solution neutral versus being slightly biased towards the SMP foam-





4. DESIGN PLAN FOR COMPLETING AIM I AND AIM II 
 
 The design process for the NED system follows the design controls mandated by 
the QSR as outlined in the FDA guidance document, “Design Control Guidance for 
Medical Device Manufacturers”.  Considering the NED is listed as a Class II device, it is 
a QSR requirement to, “establish and maintain procedures to control the design of the 
device in order to ensure that specified design requirements are met.”
31
 The QSR 
provides the framework for medical devices to be designed and manufactured according 
to procedures that produce safe and effective devices for their intended use.  The 
traditional design approach employs a waterfall model (Fig. 5).  The design is developed 
in a logical sequence of stages.   The output of one stage is the input for the next.  The 
model illustrates the iterative nature of the design process as stages are reviewed, 
verified, and validated.  As the design process evolves, improvements can be identified 
and incorporated into the medical device.  This design approach ensures the design 
outputs are a result of the design inputs and that the medical device maps to the user 
needs.   
 
 









 The first step in the design process is gathering the user needs and then 
translating them into design inputs.  Benchtop tests are necessary to verify that the 
design requirements are met.  Verification results are fed back into the design inputs to 
modify and improve the device design.  Once all the design requirements have been met 
in benchtop testing, they are ultimately validated with the use of animal models and 
clinical studies.  Again, information from the initial animal studies is fed back into the 
design process to validate that the device conforms to user needs and its intended use.   
 Due to the novelty of the NED, delivery pusher, and detachment mechanism; this 
design approach will be followed to comply with the QSR.  However, guidewires, 
guiding catheters, and microcatheters that have already been cleared by the FDA will be 
























5. AIM I: PROBLEM STATEMENT 
 
 The first specific aim is to develop user requirements and performance 
specifications for a novel NED system.  The system will comprise the NED, delivery 
pusher and detachment mechanism (P&D).  To achieve this aim, the following list of 
design tools is utilized: customer interviews, activity diagrams, functional models, 
benchmarking, human factors engineering (HFE), House of Quality (HOQ), and failure 
modes and effects analysis (FMEA).  The performance specifications are completed with 
verification tests that will ultimately need to be validated in an animal study.      
 To begin the product development process it is important to first understand the 
needs of the customer.  Customer comments, though, can sometimes be subjective, 
biased, or vague.  For this reason, they need to be translated into engineering 
requirements that can be verified through bench-top testing.   
 Activity diagrams and functional models are used to help identify latent needs 
that are not discussed in the interviews.  Activity diagrams provide a way to visually 
organize how the NED is used within a catheterization laboratory.  Functional models 
define the functions of the NED system and each subsystem.   
 Benchmarking can highlight where the current NED prototypes may excel or 
highlight design deficiencies that need improvement.  HFE principles are incorporated to 
ensure the interface controlling the delivery pusher and detachment mechanism is 
intuitive and user-friendly.  Once these are complete, a HOQ matrix is constructed to 
quantify with a measurable metric the relationship between the customer need and the 
corresponding engineering requirement.  Due to the inherent risk associated with 
endovascular procedures, a risk analysis is important to identify unanticipated device-
related hazards and include these risks into a risk management process.  To identify and 








6. USER NEEDS 
 
6.1 Customer Interviews 
  
 To begin implementing design controls, it is important to understand the needs of 
the customer.  One noted study, Project SAPPHO, found that understanding the needs of 
the customer is the most important aspect in designing a successful product.
32
  
Successful products meet the customers’ needs, have unique features not available on 
competitive products, or solve a problem the customer has with existing products.
33
  The 
customer in this sense is defined as the end user of the product.  This definition means 
the customer is not the patient but rather the interventional neuroradiologist who will be 
implanting the device.   
 Customer comments were gathered through an email exchange between Tony 
Boyle and Dr. Hartman, an interventional neuroradiologist at UCSF.  Two face-to-face 
interviews were held at Texas A&M University; one with Dr. Miller, a professor of 
Cardiology and one with Ms. Grinde, a Research Associate.  
 To gain an understanding of the use environment, a clot extraction procedure was 
observed in a catheterization laboratory.  The procedure was conducted at St. Joseph 
Mercy Oakland in Pontiac, Michigan.  Witnessing the procedure provided the 
opportunity to see how the doctors, nurses, and technicians all interacted, how the 
imaging technology was utilized, and how the device was prepared prior to implantation.  
A lesson learned from the experience is the fact that most catheterization laboratories use 
bi-planar X-ray imaging.  This technology necessitates that the embolization device be 
radiopaque so that the medical personnel can observe the device in vivo.   An 
observation that could affect our specific design was at one point a new catheter, 
preloaded with a device, was flushed and sat in a saline bath for over forty five minutes.  
This observation is important because the Tg of SMP has been found to significantly 
decrease after immersion in water.
34
  This effect will greatly influence the working time 





6.2 Customer Needs Assessments 
 
 Considering that customer comments are normally qualitative and subjective, 
they needed to be translated into needs statements.  The comments and suggestions 
recorded during the interviews were interpreted to define what the NED system needs to 
do.  That way the development team has concise, clear, and definitive statements to 
begin the design.  The process of translating the raw customer data followed a five step 
approach.
35
   
 Each customer need was expressed in solution neutral terms.  Not defining how 
the NED system is to achieve the need allows the design team flexibility. 
 Each customer need was expressed as specifically as possible to avoid confusion 
later when translating to performance specifications.     
 Each customer need was worded with positive, not negative phrasing.  
Application of the need is easier when expressed positively. 
 Each customer need was written as an attribute of the NED system to ensure 
consistency when converting into performance specifications. 
 Words such as ‘must’ and ‘should’ were not used in an attempt to remain 
objective and avoid assigning a relative importance. 
 Once the customer interviews were completed, the needs were sorted according 
to specific categories.  The categories were generated from the subsystems within the 
NED system and some of the functions that were defined from the Function Models 
described later in Section 7.  The list of categories includes: ease of use, pusher, 
detachment, actuation, and size (Table 2). 
 A subjective importance rating was assigned to each device need.  The rating 
system will help guide the development team when trade-offs and compromises need to 
be made while designing the NED system.   The importance rating has a range of 1-5.  A 
rating of 5 is a MUST need which is used when the customer must have that feature.  A 
rating of 4 is a GOOD need which is a very important customer need.  A rating of 3 is 





designated for a NICE need which would be nice if the device met the need but is not 
critical.  A rating of 1 is a MAYBE need which can be interpreted as an optional 
requirement.36   
 
Table 2. Customer Needs Assessment from Interview with Dr. Jonathan Hartman 
Date: July 
15, 2011 
End User: Dr. Jonathan Hartman 
Job Title: Interventional Neuroradiologist 
Sacramento Medical Center 









Flushed with saline solution continuously during the 
procedure 
The NED has a working time 
of 10-15 minutes once placed 
in the microcatheter 
5 
The time that each individual coil is in the microcatheter 
during deployment also varies with how difficult it is to 
put in or how difficult it is to achieve a decent 
configuration. Range is probably one minute on the low 
end and 5-10 minutes on the high end 
Similarity to prior technology and ease of use are 
definitely a plus in terms of adoption 
The NED behaves and 
actuates similarly to predicate 
devices 
4 
Total procedure can last on the short end, 1 hr.  On the 
long end, 5-6 hrs. 
The NED can withstand 6 hrs. 
exposure time to saline 
1 
Pusher As part of safety, ease of retrieval is a big issue 
The NED can be retracted 
back into the microcatheter 
after partial deployment at 




The main considerations for any device of this type are 
that it should be predictable in behavior, easily 
controlled/manipulated, and safe 
The NED is easily pushed and 
pulled through the 
microcatheter 
5 
The NED retains its crimped 
form until actuation 
5 
Laser light actuation with need for eye protection-->not 
likely to be adopted unless there is a major advantage... 
one button to push to actuate-->highly likely to be 
adopted 




Active control is a plus over passive (i.e., actuation by 
external heat source as opposed to by body 
temperature), although is not totally necessary 





 Basic product development resources were also studied to uncover latent 
customer needs that were not identified in the interviews.
32,36-38
  The comprehensive list 
focused on identifying constant and general needs that were not necessarily discussed in 
the interviews (Table 3).  The remaining customer need assessments and market research 





Table 3.  Customer Needs Assessment from Basic Product Development Research 
Date: February 
10-15, 2012 
Product Development Research Neurovascular Embolization Device (NED) 
Category Question/Prompt Interpreted Need 
Application 
What is the purpose of the NED? 
The NED is intended for embolization of intracranial 
aneurysms 
How will the NED be selected for 
use? 
After consultation with a neurosurgeon and 
interventional neuroradiologist about the health of the 
patient and size and location of the aneurysm 
How will performance be measured? 
Ease and success of delivery 
Occlusion percentage 
Competition 
What are current treatment options? 
Current options include coiling, embolic agents, 
stenting, and clipping via surgery 
How will the NED differ from 
current devices on the market? 
The NED will provide superior embolization of the 
aneurysm compared to current devices 
Customer 
Who will use the NED?   
The NED will be implanted by a interventional 
neuroradiologist 
What is the user's familiarity with 
the device technology? 
Devices have been on the market for 15 years and over 
200,000 have been implanted 
How much time is the physician 
willing to spend implanting? 
The NED will have a working time similar to predicate 
devices 
How much user training is required? 
The NED design and delivery will be simplified to avoid 
complicated training 
What user characteristics affect what 
the NED must be like?   
Predicate devices have set the precedent for familiarity 
and comfort 
Environment 
Where will the procedure for 
implanting the NED take place? 
The NED will be implanted in a Catheterization 
Laboratory 
Product Life Span How often will the NED be used? The NED will be a single use device 
Life in Service How long will the NED be in use? The NED will be implanted for the life of the patient  
Weight 
Will weight or density affect 
delivery of device? 
The NED will be compliant enough to navigate tortuous 
vessels 
Safety What are the safety concerns? The NED will be safe and effective for its intended use 
Maintenance 
How will adjustments and 
monitoring of the NED be done? 




What quality is needed? 
The NED will be of high quality to ensure it can be 
implanted correctly and stay within the aneurysm long-
term 
Storage 
Will the NED be stored in a sterile 
and non-pyrogenic environment? 
The NED will be packaged to maintain a sterile and 
non-pyrogenic environment 
Within what humidity and 
temperature range does the device 
need to be stored? 
The NED will have instructions for proper storage 
Will the NED be easy to store? 
The NED will be packaged similarly to predicate 
devices 
Shipping Does vibration affect actuation? The NED will pass necessary vibration testing 
Label Label must define intended use 









Is certain equipment necessary? 
The NED will be manufactured according to GMP 
regulations 
Testing Conduct applicable bench tests 
The NED will undergo the same bench testing as 
predicate devices 
Shelf Life 
What is the expected shelf life of the 
NED? 
TBD 






6.3 Activity Diagram 
 
 Another tool used to identify user needs was an activity diagram which maps out 
the life cycle of the NED.  Activity diagrams examine the customer and product 
interaction to identify customer needs.  They are used as a graphical model to aid 
communication, organize the flow of design, and also as a way to accelerate the 
understanding of the design.38  The implant procedure is a structured set of activities 
performed to produce a specified output.  The output is defined as the successful 
occlusion of the aneurysm with minimal risk of re-bleeding or recanalization.   
 The activity diagram is broken into three stages; preparation, implantation, and 
follow-up (Fig. 6).  From the diagram it is seen that the interventional neuroradiologist is 
the end user of the device and the patient is an indirect user.  Some customer needs can 
be derived from the interaction between the device and the user.  During the preparation 
stage, the device will be placed into a saline bath, thus necessitating the need for an 
established working time.  The ability to push and pull on the device to obtain proper 
position before detachment will be an important parameter to monitor during the 
implantation stage.  Finally during follow-up, the NED will need to be radiopaque in 




















7. FUNCTIONAL MODELS 
7.1 Functional Models 
 
 A design technique known as functional modeling is used to ensure the design 
inputs of the NED system follow the user needs.  Functional models simplify the 
medical device into the main functions it must perform to meet the user needs.  A 
function is a declaration of a clear, repeatable relationship between an input and the 
desired output, while remaining independent of any particular form.
36
  The product 
function is a simple representation of the product and is phrased as a combination of a 
noun and an active verb.  The models decompose a problem into simpler sub-problems 
by focusing on what the device must do not how it will do it.  This technique enables a 
solution neutral expression of the design task so a comprehensive search for solutions 
can be achieved later in the design process.  The product function is then decomposed 
into sub-functions that correspond to subtasks which when taken together satisfy the 
overall function. 
  
7.2 Functional Analysis System Technique  
 
 The first functional model that was constructed applied a top-down approach.  
The Functional Analysis System Technique (FAST) was used to define, examine, and 
understand the product sub-functions (Fig 7).  The functional model can illustrate how 
the functions relate to each other and which functions have a higher priority for the 
design team.  The functions were phrased with a verb and noun structure and were 
worded as broad and generic as possible.  Phrasing the functions in broad terms can 
minimize any potential bias and allow the true crux of the problem to be realized.   
 The overall product function needed to be determined in order to assemble the 
functional model.  The overall product function represents the main reason for the 
product’s existence.  The overall product function of the NED system is to occlude 





product function.  The critical path was established by determining the string of sub-
functions that are critical to the NED system achieving its intended use.  The overall 
product function was listed to the far left of the diagram and the sub-functions were 
placed to the right.  Each node to the right in the critical path answered the question of 
how the left node was achieved.  For example, the NED can only be implanted into the 
aneurysm after it has been released.  It can be released only after it has been properly 
delivered.   
 The rightmost extreme of the critical path is a sub-function not performed by the 
device and once it was reached, the system boundary was defined.  The critical path 
functions can be decomposed into lower level sub-functions that are caused by the 
critical path.  Sometimes unwanted side-effects are created when achieving the sub-
functions.  Therefore, new functions arise to mitigate the side-effects and are placed 
under the critical path function that caused them.   
 Other functions that are not part of the critical path in any way are placed above 
the functional model.  The objective of the NED system is placed on the left, one-time 
functions in the center, and all-time functions on the right.  The objective of the NED 
system is to provide superior occlusion compared to competitive coils.  The one-time 
function is to protect the NED system during shipping and storage.  The all-time 
functions that are always present include: behaving like similar devices, ensuring the 













7.3 Subtract and Operate Procedure 
 
 The Subtract and Operate functional model applied a bottom-up approach.  The 
smallest functions were first defined as those that could not be decomposed into further 
sub-functions.   The component that supplied these smallest sub-functions were 
identified and then conceptually removed.  By subtracting the component from the NED 
system, the critical contribution of that component is established.   Once the component 
is subtracted, the NED system is tested on a conceptual basis to determine what 
important sub-functions were lost (Table 4).  The components and features that are 
responsible for the primary sub-functions of the NED system are the guidewire and 
catheters, introducer sheath, delivery pusher, detachment mechanism, actuation method, 
and radiopacity. The sub-functions were then translated into a function tree (Fig. 8).  The 
sub-functions were collected into common groups of functional description. The higher 
level sub-function nodes were placed above the lower level sub-functions until the 
function tree converged at the top into the overall product function. 
 





Pusher Detachment  Actuation Radiopacity 




No way to 
secure NED in 
catheter 
Difficult to navigate 
tortuous vessels to guide 








 No protection 
of foam from 
plasticizing 
agent 
Difficult to properly 
position/reposition NED 










 Difficult to 
minimize 
sliding friction 






 Difficult to 
minimize 
torque 
    













8.1 Benchmarking Data for Current NED Systems on the Market 
 
 Benchmarking generates data to help clarify user requirements and understand 
current market products and technology trends.  Benchmarking provides a standard for 
judging quality, performance, and value.  The best-in-class product can be identified and 
studied to determine what attributes make it the best.  These features can then be 
emulated and incorporated into the performance specifications.  The design team must 
understand the market demand for a particular product and how competitors meet it.  
Designing similarity into the NED system aids in familiarity for the medical personnel.  
The benchmarking analysis for the NED system was carried out in a four-step process.   
Step 1:  Formed a List of Competitive Products 
 The trade magazine Endovascular Today, 2012 BUYER’S GUIDE39 was 
consulted to obtain a comprehensive listing of all the FDA-cleared NED systems 
available in the United States.  All competitors and their different product models 
were listed.  This list included each product launched under common platforms.   
Step 2:  Conducted an Information Search 
 To properly benchmark the NED systems, it was important to gather as much 
information as possible.  Information about each NED was taken from a variety 
of sources; marketing literature from applicable company websites, each 
product’s Instructions for Use, published case studies, 510(k) and humanitarian 
device exemption (HDE) submissions, published adverse events from the 
MAUDE database published on www.FDA.gov, and the FDA guidance 
document, “Class II Special Controls Guidance Document: Vascular and 
Neurovascular Embolization Devices” (Table 5).  The needs identified in the 
customer assessments were also referenced.   





 A list of design issues were developed from the information search conducted in 
Step 2.  Particular attention was paid to what materials the devices were made 
from and how the devices functioned.   
Step 4:  Benchmark by Function   
 The functional models from Section 7 were studied to help organize the 
benchmarking data.  Three prominent sub-functions stood out as important to 
achieving the overall product function.  From this analysis, the NED system was 
broken down into three sub-systems; the NED (Table 6), the delivery pusher 
(Table 7), and the detachment mechanism (Table 8).  The acronym, ID, stands 
for the inner diameter of the microcatheter that is used for each coil. 
 
Table 5.  Benchmarking List of 510(k) and HDE Submissions 






MicroCoil Delivery System K002056 1/11/2001 
TRUFILL Detachable Coil System  K014041 3/7/2002 
MicroCoil System K031578 8/1/2003 
MicroCoil System K033813 2/4/2004 
TRUFILL Detachable Coil System K063254 12/7/2006 
Orbit GALAXY Detachable Coil System K093973 5/26/2010 
Covidien Sapphire Detachable Coil System K030392 7/21/2003 
Sapphire Detachable Fiber Coil System K031852 8/20/2003 
Sapphire Detachable Fiber Coil System K033372 1/9/2004 
Sapphire NXT Detachable Coil System K041649 7/16/2004 
Nexus Detachable Coil System K050543 4/27/2005 
Nexus Detachable Coil System K060625 4/20/2006 
MicroVention 
TERUMO 
MicroPlex Coil System  K012145 10/29/2001 
MicroPlex Coil System and HydroCoil Embolic System with 
the HydroLink Syringe Kit 
K022735 9/6/2002 
MicroPlex Coil System (MCS) HydroCoil Embolic System  K032590 10/22/2003 
HydroCoil Embolic System  K070656 6/15/2007 
HydroCoil Embolic System  K100454 4/22/2010 
HydroCoil Embolic System, HydroSoft Plus K113457 12/16/2011 
Penumbra Penumbra Coil System / Penumbra Coil 400 K103305 1/26/2011 
Stryker 
Neurovascular 
Guglielmi Detachable Coils  K962503 9/20/1996 
Guglielmi Detachable Coils K971395 7/14/1997 
Guglielmi Detachable Coils K993418 1/21/2000 
Matrix Detachable Coils K012985 1/31/2002 
Guglielmi Detachable Coils (GDC) Power Supply K021494 6/6/2002 
Target Detachable Coils InZone Detachment System K093142 2/4/2010 
Target Detachable Coils  K102672 10/15/2010 
Target Detachable Coils  K112385 9/15/2011 









Table 6.  Benchmarking Data for Currents NEDs on the Market 
Company Trade Name Materials Used Type Shape Working 
Time 
(min.) 
























































& Au/Sn solder or 
Cerecyte® - stretch-
resistant, absorbable 
PGA or non-absorbable 
polypropylene filaments 









































Finish Spherical , 
helical 
















Fill Straight Infinite Yes Yes 10 ID 0.014-0.017 4-6 10-30 
MICRUSPHERE 
Microcoils 
































Bare platinum, PGLA 















Platinum alloy enlaced 
with absorbable polymer 
microfilaments.  Stretch- 











Company Trade Name Materials Used Type Shape Working 
Time 
(min.) 












Platinum/iridium alloy  
and Nylon 6-6 fibers, 




Helical Infinite Yes Yes 10 
18 
0.010-0.018 2-15 2-30 
MicroVention 
TERUMO 




Complex Infinite Yes Yes 10 
18 
0.0085-0.015 2-20   
Complex Coils Frame, 
fill 
Complex Infinite Yes Yes 10 
18 
0.0095-0.015 2-20   
Cosmos Coils Frame Complex Infinite Yes Yes 10 
18 
0.010-0.015 2-24   
Helical Coils Fill, 
finish 
Helical Infinite Yes Yes 10 
18 
0.0095-0.014 2-20   
HyperSoft Coils Fill, 
finish 




(92/8) with outer layer 
hydrophilic acrylic 
polymer.  Cross-linked 
copolymer - acrylamide 
















Frame Helical 30 Yes Yes 10 
18 




Finish Helical 30 Yes Yes 10 0.013 1.5-10 2-30 
 
Penumbra Inc. Penumbra Coil 
400 
Platinum/Tungsten alloy 
(92/8) wire with stretch-













Detachable Coils  
Platinum/Tungsten alloy 










Infinite Yes Yes 10 
18 

































Straight Infinite Yes Yes 18 0.016 N/A Up to 
80 




Table 7.  Benchmarking Data for Current Delivery Pushers on the Market 












High tensile strength, highly oriented 
polyethylene fiber. Mechanical 







Stainless steel hypotube 
(proximal), stainless steel braid 
(mid), nitinol and platinum, 
polymer (distal) sheathing for 2 
copper conduction wires and 





Soft polymer gripper, slide coil into 
polymer delivery tube 
Tube designed to 
protect coil 
Tube comprised of hub, strain 
relief, stiff proximal section, 




Floating eyelet Introducer sheath Hypotube composite with 




Laser welded  Teflon outer jacket Stainless steel wire with 
radiopaque positioning coil 







Proximal end of coil incorporates 
platinum/iridium (90/10%) coupler and 
a polyolefin elastomer. Filament runs 
through inner lumen of coil coupler and 
is attached to distal end of Pusher 
Introducer sheath on 
outside of delivery 
pusher 
Variable stiffness, stainless steel 
pusher and tapered mandrel, 2 
layers of PET tubing cover distal 
end, layer of polyimide tubing 




PET tubing is heat shrunk over 
coupler/pusher junction to act as 
retention sleeve 
2 outer layers of PET 




Variable stiffness, stainless steel 
tube with several outer layers of 
PET tubing, luer hub at proximal 




Ball and socket N/A Flexible Nitinol coil reinforced 
PTFE-lined pusher.  Stainless 







Welded or soldered to delivery pusher, 
laser ablated/etched 
High density 
polyethylene introducer  
 
Ground 316LVM stainless steel 
delivery wire, Teflon outer 
jacket at distal section, flushing 
dispenser coil assembly  
0.0090 50-200 
GDC Pusher Soldered to delivery pusher N/A Ground stainless steel core wire, 












NeuroVasx Inc. Pusher Polyethylene bridge N/A Hydrophilic coated polyethylene 
shaft with polyurethane strain 
relief, polycarbonate hub, 
hemostasis valve 
 160 





Table 8.  Benchmarking Data for Current Detachment Mechanisms on the Market 
Manufacturer Coil 
Compatibility 








































14-cc syringe barrel 
with pressure gauge, 
threaded plunger 






























for 5s while 
detaching 
Self-grounded, closed 
circuit.  Lithium Ion 
eliminates battery 
























ball and socket 
Thumb 
slide 















































Battery 0.75 Hand-held 20 




connecting cables, or 
additional batteries. 2 
silver electrical leads 
run along outside of 
mandrel. Platinum 
and stainless steel 
wires wound around 



























at proximal end 
of Pusher 
Syringe N/A instant Hand-held N/A N/A8 














ball & socket 
Thumb 
slide 










































5 Hand-held 1 






















audible tone  
Core wire with 
electric lead wire 
attached to heater coil 
at distal end 





9. PERFORMANCE SPECIFICATIONS 
 
9.1 Human Factors Engineering  
 
 Implementing Human Factors Engineering (HFE) principles into the design of 
medical devices reduces the risk of injury or death to the patient.  This focus is 
accomplished with the careful and systematic design of an effective user interface that is 
compatible with the abilities of the user population.   
 To eliminate user error it helps to design the product to be similar in form and 
function to what is currently being used in clinical practice.  People tend to respond to 
new situations based on established habits.  An intuitive design that is comparable to 
existing technology helps to reduce potential problems.  The following general rules of 
thumb will be considered for the hardware and possible software performance 




Table 9. Human Factors Considerations  
Category Human Factor 
User The interface is consistent with user expectations, keeping in mind the user’s prior experience and 
well-established conventions 
The basic capabilities of the user such as strength, memory, reach, vision, hearing, and dexterity 
Controls  Any control switches and knobs correspond to normal conventions and are arranged and spaced to 
avoid accidental activation 
 Any controls provide tactile feedback 
Sound  The pitch and intensity of any auditory signal can be heard easily above ambient noise 
Visual 
Display 
The brightness of displays can be perceived by users under different ambient illumination. 
 The displays can be viewed from multiple distances and angles, keeping in mind contrast, color, and 
symbol size 
 The controls and display arrangements are well-organized and the association between the controls 
and displays is obvious 
 Any symbols, text, and abbreviations follow conventional standards and are defined in the user 
manual 
Data Input Use conventional symbols, colors, abbreviations, and formats 
 Keeps users aware of the device status at all times 
 Provide clear and immediate feedback 
 Use prompts and menus to guide the user 
 Provide a way to correct input errors 
Data Output  Convey information quickly and reliably, using conventional symbols, colors, abbreviations, and 
formats 
 Use dedicated displays for critical information 





 Benchmarking results from Section 8 were reviewed to accommodate the user 
needs.  Anthropometric data was analyzed to supply necessary information for the sake 
of assessing portability of a potential external controller for the detachment mechanism.  
The anthropometric data guided the process of selecting sizes and can help determine the 
proper placement of any control switches or knobs.  Considering interventional 
neuroradiologists come from ethnically diverse populations, it will be important to 
understand the variation in sizes.  At a minimum, the design should accommodate adults 
who range from the 5
th
-percentile female to a 95
th
-percentile male in size.
41
   
 Potential specifications for the sound and visual display of an alarm system or 




Table 10. Auditory and Visual Display Specifications for Feedback Signals 
# Functional Requirement Unit Upper Limit Lower Limit Ideal Direction 
1 Auditory frequency range for fundamental Hz 1000 150 + 
2 Auditory frequency range for harmonics Hz 4000 300 + 
3 Auditory pulse ON time S 0.2 0.075 + 
4 Auditory pulse OFF time S 0.125 0.05 + 
5 Auditory rise time % 20 10 + 
6 Auditory loudness dB 25 15 + 
7 Visible brightness distance m 10 4 + 
8 Visible color Color red yellow + 
9 Visible flashing frequency Hz 2.8 1.4 + 
10 Visible ON duty cycle % 60 20 + 
 
 
9.2 House of Quality 
 
 The next step in the design process was to create the design inputs known as the 
performance specifications.  This was no trivial task as the establishment of performance 
specifications for a product is the most important aspect of the design process.
35,4231
  The 
specifications were developed by tying together the needs from the customer interviews 
and the data from benchmarking activities using a House of Quality (HOQ) matrix for 
the NED (Table 11), and for the delivery pusher and detachment mechanism (Table 12).  
A HOQ is a conceptual map that aids in functional planning and communication.
43
  It is 





requests, converting them into engineering requirements, establishing target 
specifications, and then showing how everything is related together. 
 The HOQ was built by first listing and organizing the customer needs with their 
subjective importance ratings according to their specific categories.  The customer 
needs, though, only mentioned what the device should do.  They needed to be translated 
into engineering requirements to describe how the device would satisfy the needs.  
Along the top of the HOQ, engineering requirements were placed that affect one or more 
of the customer needs.  The engineering requirements describe the NED system in 
measurable terms and are meant to directly affect customer perceptions.
43
  Sometimes a 
customer need was quite general and broad, so it required more than one engineering 
requirement to fully satisfy the need.  There are also certain engineering requirements 
the FDA has identified which were incorporated into the HOQ. 
 
 coil strength (i.e., the force required to deform the coil shape – primary and 
secondary diameters, as well as coil tensile strength, torsional resistance and 
fatigue) 
 ease of delivery, as measured by friction when advancing and/or retracting 
the coil through a recommended catheter positioned in a simulated tortuosity 
 for coils with fibers, a description of the fiber attachment mechanism and 
pull-out force 
 a description of the detachment mechanism and data on the detachment time 
 reliability of the detachment mechanism.44 
 
 The next step was to fill in the body of the house by evaluating the strength of the 
relationship between the customer needs and the engineering requirements.  A rating of 
9 was used for strong relationships, 3 for moderate, and 1 for weak.  At the bottom of the 
house, the technical importance ratings were calculated by taking the sum of the 
products between the strength of a particular engineering requirement and the subjective 
importance rating of each customer need.  The technical importance rating can highlight 
significant engineering requirements that require attention.  Results from benchmarking 
data, relevant scientific literature, and 510(k) and HDE submissions were reviewed to 





upper limit for the target values along with an ideal direction was defined and placed 
below the technical importance rating.  The ideal direction provides guidance about 
whether the design should strive to achieve the upper or lower limit.   
 Finally, the roof of the house was filled in by determining the correlations 
between the engineering requirements.  Each engineering requirement was evaluated 
against all the other engineering requirements to determine how various aspects of the 
NED system are all related.  This data highlights the interrelationships between 
requirements and illustrates how changing one requirement could have a ripple effect on 
the rest of the design.  A rating of 2 was used for a strong positive correlation, 1 for 
moderate positive, a blank space for no correlation, and ‘-‘, for a negative correlation.  
For example, if the design team wants to increase the filling percentage in order to 
achieve greater occlusion of the aneurysm, at first thought it seems like a good idea since 
the technical importance rating is 168.  However, achieving a higher filling percentage 
will most likely require more foam volume, which would have a negative impact on the 
crimped diameter.  When taking into consideration the fact that the crimped diameter has 
a higher technical importance rating of 268, the design team may reevaluate their 
decision about increasing the filling percentage.  The HOQ can be used as a guide for the 
design team to help prioritize the engineering requirements.  The HOQ can highlight the 
















1 Filling percentage                             
2 Coils used 2                           
3 Radiopacity 1 1                          
4 Crimped diameter -  -                         
5 Sharp edges or corners                            
6 MRI - Static magnetic field   -                         
7 MRI - Spatial gradient field   -   1                      
8 MRI - Max averaged specific absorption rate (SAR)   -   1 1                     
9 Advancement force    1 1                       
10 Retraction force    1 1    1                   
11 Prep time                            
12 Axial shear    1 1    2 2                  
13 Circumferential shear    1 1    2 2  1                
14 Minimum radius of curvature    1 1    2 2  1                
15 Working time    -     1 1 1 1 1 1              
16 Particulate generation            1   1             
17 Complete retractions into sheath after 90% deployed    1 1     2  2 1 1 2 2            
18 Complete retractions into microcatheter after 90% deployed    1 1     2  2 1 1 2 2 2           
19 Tip deflection force   - 1 1    2 2    2 1             
20 Shape memory recovery of foam 1 1               - -          
21 Shape recovery forces of foam 1 1               - -  2        
22 Force required to deform primary coil shape 1 1               - -  1 1       
23 Time to learn actuation method           1                 
24 Actuation time 1 1             -  - -  1 1 1 1     
25 Physiologically compatible temperature 2 1          1 1 1     1 1  1  2    
26 Range of device lengths 2 1       1 1    2     1         
27 Range of coiled diameters 2 1       1 1    2     1       2  
  Engineering Requirements 



























































































































































































































































































































































































































































Visible under fluoroscopy during/after implantation 5 3  9   1 1 1            3 3 3      
Easily pushed and pulled through the microcatheter 5    9 3    9 9  3 3 9 9    3         
Withstand being twisted and bent 5    3 1    3 3  9 9 9 3 3   1       1  
Working time of 10-15 minutes once placed in the microcatheter 5    3     1 1 9    9 3 9 9 3     1 3   
Use fewer coils to provide superior embolization of the aneurysm 
over time compared to current devices 
4 9 9 3 3                3 3 3  1 3 9 9 
Similarity to prior technology and ease of use are definitely a plus 
in terms of adoption 
4 3 1 9  9 9 9 9 9 9 3 9 9 9 9  9 9 9    3 3 9 9 9 
MR conditional 3   3   9 9 9                    
Ready to use right out of the package 3    3 1      9            3  1   
Withstand 6 hrs. exposure time to saline 1    1       9    9 3         1   






Pusher Retracted back into the sheath and repositioned after partial 
deployment at least once 
5    9 3    3 9  9 3  9 9 9  3 3 3 3  9 3  3 
Retracted back into the microcatheter after partial deployment at 
least once with the NED in any configuration 
5    9 3    3 9  9 3  9 9  9 3 3 3 3  9 3  3 
Foam pieces do not break off when retracted 5    1 1     3  9   3 9 9 9  1 3      1 
Retracted and repositioned 2-3 times is preferred 3    9 3    3 9  3 1  9 9 9  3 3 3 1  9 1  3 
Detach Does not alter the position of the microcatheter during positioning, 
detachment, and actuation 
5    3 3    9 9  3 1 9 3    9 3 1   3 3   
Remain in the aneurysm once detached 5 9 3  3            9    9 9 3  9 3 1 1 
Actuate Retains its crimped form until actuation 5    3       3    9  3 3      9 3   
Actuates into stable, known configuration and diameter 5 3 1             1     9 9 9  3 3 1 1 
Actuates to cover the neck of the aneurysm 4 9 3  1           1     3 3 9  3 3 1 1 
Simple to use, straight-forward actuation method 4           9    3        9 3 3   
Conform to range of shapes 3 3 1  1                9 9 3  3  9 9 
Active user-controllable actuation 2               3        3 9 3   






















































































































































































































































































































































































Table 12. House of Quality for the P&D 
1 Radiopacity                   
2 Outer diameter  -                  
3 Working length 1                  
4 Sharp edges or corners                   
5 Advancement force  2  1               
6 Retraction force  2  1 1              
7 Prep time                   
8 Tensile strength of NED and Detachment zone      2             
9 Tensile strength of Detachment zone and Pusher      2  1           
10 Tip deflection force  1  1 2 2             
11 Buckling force  1  1 1              
12 Detachment time                   
13 Reliability after fatigue        1 1 1  1       
14 Time to learn how to detach NED       1      1      
15 Exchanges through guiding catheter            1 1      
16 Length of controller                   
17 Diameter of controller                   
18 Weight of controller                - 2  
 Engineering Requirements 
































































































































































































































































































Visible under fluoroscopy during implantation 5 9 3 1                
Withstand being twisted and bent 5  3  1 3 3  1 1 1 1        
Ready to use right out of the package 3  3 3 1   9       3  1 1 1 
Pusher NED retracted back into the micro-catheter and repositioned after 
partial deployment at least once.   
5    3 3 9             
Removed from the body with the NED in any configuration 
Retracted back into the microcatheter after partial deployment at least 
once 
5    3 3 9             
Delivery Pusher does not alter the position of the microcatheter 
during positioning, detachment, and actuation 
5  1  3 9 9 3 1 3 9   1      
Delivery Pusher is easily pushed and pulled through the 
microcatheter 
5     9 9             
Detach Detachment mechanism does not alter the position of the 
microcatheter during positioning, detachment, and actuation 
5  3 1 3 9 9  3 3 9 3 3 1      
Detachment is easily pushed and pulled through the microcatheter 5  3 3 3 9 9  9 9 3 9        
Immediate and reliable 5            9 9      





Actuate Less number of exchanges through guiding catheter the better 3               9    















































































































































































































































10. RISK ANALYSIS 
 
10.1 Failure Modes and Effects Analysis 
 
 Endovascular treatment is a complicated and delicate procedure incorporating a 
team of medical personnel and highly sophisticated technology.  The technical failure 
rate for procedures has been reported to range between 4.8% to >10%.
13
  Therefore, 
there are certain risks the FDA has identified that require mitigation measures to be 
taken (Table 13).  Risk management begins once the performance specifications are 
defined.  A risk analysis is necessary to evaluate the proposed specifications against any 
risks imposed by the NED system.     
 
Table 13. FDA Identified Risks for NEDs
44
 
Identified Risk Recommended Mitigation Measures 






















 A Failure Modes and Effects Analysis (FMEA) was performed to identify any 
other risks specific to the NED system.  The results of the FMEA were based on 
previous prototype testing done by Wonjun Hwang in the Biomedical Device Laboratory 
and reviewing adverse events listed on the MAUDE database published on 
www.FDA.gov.  The results of the MAUDE research can be found in Appendix B in 





 Only one FMEA was constructed because the process inherently focuses on the 
entire product layout, not just individual components or subsystems.  There are three 
basic elements of FMEA: failure modes which involve identification, failure effects 
which involve ramifications, and failure criticality which measures the relative 
importance of a failure.   
 Each component of the NED system is listed in the FMEA along with the basic 
functions taken from the functional models described in Section 7.  Three categories are 
used to examine each failure mode.  The first category is the potential effects of the 
failure modes.  The idea is that the failure could occur before, during, or after being 
implanted into the aneurysm.  The severity of the failure mode is estimated and given a 
number based on a defined scale (Table 14).   The second category is a potential root 
cause of the failure.  The likelihood of occurrence of the potential root cause is rated and 
given a number based on a defined scale (Table 15).  The third category is the design 
controls and testing that are in place to detect the failure from occurring.  The likelihood 
of detection is intended to estimate how well the control will detect a failure mode 
before the customer is affected and it is given a number based on a defined scale (Table 
16).   
 
Table 14. Ratings for Potential Severity (S)
36
 
Ratings for Potential Severity (S) 
1 No effect 
2 Very minor (only noticed by discriminating customer) 
3 Minor (affects very little of the system; noticed by average customer) 
4/5/6 Moderate (most customers are annoyed) 
7/8 High (causes a loss of a primary function; customers are dissatisfied) 
9/10 Very high and hazardous (product becomes inoperative; customers are angered; the failure may result unsafe 
operation and possible injury) 
 
 
Table 15. Ratings for Likelihood of Occurrence (O)
36
 
Ratings for Likelihood of Occurrence (O) 
1 No effect 
2/3 Low (relatively few failures) 
4/5/6 Moderate (occasional failures) 
7/8 High (repeated failures) 






Table 16. Ratings for Likelihood of Detection (D)
36
 
Ratings for Likelihood of Detection (D) 
1 Almost certain 
2 High 
3 Moderate 
4/5/6 Moderate – most customers are annoyed 
7/8 Low 
9/10 Very remote to absolute uncertainty 
 
 
 The Risk Priority Number (RPN) was then calculated based on: 
RPN = (S) x (O) x (D) 
The RPN prioritizes the relative importance of the failure modes and ranges from 1-
1000.  The higher the number: the more hazardous the failure.  An important thing to 
note is the scale is nonlinear.  Ratings above 100 will occur, while ratings below 30 
usually are reasonable and typical.
36
  The FMEA is completed with recommended 
actions to reduce the risk (Table 17).  The RPN can be referenced to determine the 
failure modes that require immediate action.  Some corrective actions that can be 
implemented include revised sub-system design, revised verification tests, updated 
material specifications, or new prototypes.  Once the corrective actions have been 
completed, the RPN should be recalculated to reevaluate the performance of the design.  
As an example, to reduce the risk of overexpansion of the foam, there are a couple 
recommended actions that are identified.  The shape memory recovery and the shape 
recovery of the foam will need to be selected to ensure the device does not expand to 





Table 17.  FMEA for the NED System 
Component Function Potential 
Failure Mode 










Guide Catheter Position and 
secure 
microcatheter 
Fatigue Weakening of 
catheter 
6 Too many 
exchanges 
through catheter 
1 Reliability after fatigue 
testing 
2 Bench top 
testing of full 
assembly 
12 






1 Select catheter with 
established reputation 
2 Bench top 





3 Kink in line 2 Determine necessary 
radiopacity 
2 Bench top 








Stiffness Prevent delivery 8 Inadequate 
material selected 
1 Use material with 
strong mechanical 
properties 
1 Bench top 
testing of full 
assembly 
8 
Sticking Prevent delivery 6 Inadequate 
material selected 




3 Bench top 
testing of full 
assembly 
36 
Loose fittings Improper 
implantation 
6 Improper size 1 Selection of sheath 
with proper size 
4 Bench top 
testing of full 
assembly 
24 
Microcatheter Position and 
secure NED 
Fatigue Weakening of 
catheter 
6 Too many 
exchanges 
through catheter 
1 Reliability after fatigue 
testing 
2 Bench top 
testing of full 
assembly 
12 






1 Select catheter with 
established reputation 
2 Bench top 





3 Kink in line 2 Select catheter with 
established reputation 
2 Bench top 










Sticking Prevent delivery, 
remove 
microcatheter, blood 





3 Measure advancement 
and retraction forces 
3 Bench top 







Component Function Potential 
Failure Mode 















3 Determine maximum 
angle of curvature, tip 
deflection force 
2 Bench top 
testing of full 
assembly 
54 






2 Verify distal shaft of 
microcatheter is not 
under stress before 
detaching NED 
3 Bench top 
testing of full 
assembly 
60 






3 Determine distal tip 
buckling, advancement 
and retraction forces 
3 Bench top 





7 Abrasive ends or 
surface 
2 Select manufacturing 
process capable of 
smooth surfaces 
2 Bench top 
testing of full 
assembly 
28 
Fracture Prevent delivery, 




2 Determine tensile 
strength of coil and 
release zone 










2 Determine tensile 
strength of pusher and 
detachment  
3 Prototype testing 
of assembly 
60 
Misalignment Coil migration into 
parent artery 
10 Not viewable 
under 
fluoroscopy 
3 Determine radiopacity, 
tip deflection force  
4 Bench top 
testing of full 
assembly 
120 
Material Yield Prevent delivery 10 Need high 
retraction forces 
2 Use material with 
strong mechanical 
properties 
3 Bench top 
testing of full 
assembly 
60 
Oxidation Prevent delivery 7 Inadequate 
material selected 
1 Use material with 
strong mechanical 
properties 
2 Bench top 









 3 Animal testing 60 
NED Occlude 
aneurysms 








3 Animal testing 60 





Component Function Potential 
Failure Mode 










Binding Prevent delivery, 
coil migration into 
parent artery 
10 Device oversized 
or undersized for 
Detachment  
 2 Determine tensile 
strength of coil and 
release zone, 
detachment time 
4 Bench top 





10 Foam breaking 
off during 
retraction 
5 Retraction tests with 
visual inspection 
5 Bench top 
testing of full 
assembly 
250 








10 Establish working time, 
select appropriate size 
2 Bench top 
testing of full 
assembly 
100 
Stripping Prevent delivery,  




9 Foam not adhered 
to coil  
3 Axial and 
circumferential shear 
tests 
3 Prototype testing 
of assembly 
81 
Misalignment Coil migration into 
parent artery, blood 
vessel perforation or 
rupture 
10 Not viewable 
under 
fluoroscopy 
2 Determine radiopacity, 
tip deflection force 
4 Bench top 









3 Animal testing 60 
Air emboli Ischemia 10 Improper saline 
flush 
3 Continuous flush of 
catheter with 
heparinized saline 





3 Long actuation 
time, low foam 
recovery force 
2 Determine actuation 
time, shape memory 
recovery and shape 
recovery of foam 
8 Animal testing 48 
Over-
expansion 
Coil migration into 
parent artery, blood 
vessel perforation or 
rupture 
10 Too high shape 
memory recovery 
and recovery 
force of foam 
2 Determine shape 
memory recovery and 
shape recovery of foam 
9 Animal testing 180 







11.1 Verification  
  
 Adhering to the waterfall design process, the performance specifications need to 
be verified. Tests needed to be written to provide an objective method of analysis to 
prove each specification falls within the established limits. The result of each 
verification test is the design output for this stage of development.  As required in the 
QSR, verification needs to confirm that design outputs meet design inputs and the results 
are used as a key quality control technique.
31
    The verification tests for the NED have 
the method for the test as well as the acceptance criteria determined in the HOQ (Table 
18).  The same is true for the verification tests for the P&D (Table 19).   
 The methods of verification involve tests, analyses, and inspections.  
Benchmarking data, 510(k) and HDE submissions, patents, relevant scientific literature, 
and materials’ standards were referenced to construct the verification tests.  Recognized 
standards are mentioned in the verification tests as a guidance tool but complying with 
them exactly is not necessary.
44
  The verification tests are written so that all engineering 
requirements are verified in as few tests as possible.  This approach will eliminate 
















Method of Verification 
1 Filling percentage % 100 30 + Verify by calculating the volume of an aneurysm model made 
out of PDMS using the equations below as guidelines 
depending on the shape of the aneurysm.  Calculate the volume 
of the NED with expanded foam using the cylinder equation 
below.  Compare the results to the volume of the aneurysm and 
calculate filling percentage  
 
Cylinder v = πr2 * h 
Sphere v = 4/3π * r3 
Ellipsoid v = 4/3π * r1r2r3 
 
2 # of coils used # 20 1 - 
3 Radiopacity % 100 8 + Verify radiopacity by using appropriate medical imaging equipment and image the NED 
within a catheter and then compare to a metal guidewire.  Use image capturing software 
to compare the contrast in pixel intensities between the background and the NED, once 
complete compare the results between the background and a metal guidewire 
4 Crimped diameter in. 0.020 0.010 - Verify with calibrated caliper gauge to measure diameter 
5 Sharp edges or 
corners 
# 0 0 = Verify with visual inspection of the NED 
6 MRI - Static magnetic 
field 
Tesla 3 1.5 + Verify temperature rise  does not exceed  0.3°C at stated upper limit for MR system-
reported whole-body-averaged specific absorption rate (SAR) for 20 minutes of 
scanning in stated limit of static magnetic field system and stated spatial gradient field 7 MRI - Spatial 
gradient field 
Gauss/cm 720 1 + 
8 MRI - Maximum 
averaged specific 
absorption rate (SAR) 
W/kg 2 1 + 
9 Advancement force gf 50 1 - Verify advancement force of the NED does not exceed stated upper limit when tested in 
a simulated anatomical location at 37°C through various microcatheters and a 
hemostasis valve 
10 Retraction force gf 50 1 - Verify with tests 17 & 18 
11 Prep time s 120 1 - Verify the time it takes to prepare the NED for placement into the catheter once it has 















Method of Verification 
12 Axial shear  gf infinite 150 +  
Verify the adhesion strength of the wire backbone 
does not break free under axial shear load.  Secure 
the distal end of the crimped foam in a fixture within 
a calibrated load cell and pull on the delivery pusher 
and detachment mechanism to ensure the force to 
failure is more than the stated lower limit.  
 
Follow ASTM D3574 Test E for guidance 
 
13 Circumferential shear gf infinite 150 +  
Verify the adhesion strength of the wire backbone 
does not break free under circumferential shear load.  
Secure the distal end of the crimped foam in a fixture 
within a calibrated load cell and twist the delivery 
pusher and detachment mechanism to ensure the 
force to failure is more than the stated lower limit. 
  
Follow ASTM D3574 Test E for guidance 
 
14 Maximum angle of 
curvature 
degrees 180 180 = Verify the maximum advancement force and retraction force are not exceeded when the 
NED is deployed in a microcatheter and advanced/retracted through the maximum angle 
of curvature  
15 Working time min. 15 5 + Verify the NED can be fully retracted back into the sheath/microcatheter after 90% of 
the NED has been pushed out of the microcatheter when tested in a simulated 
anatomical location at 37°C within the defined working time of the foam.  (Working 
time begins when the foam is first exposed to liquid and ends when the NED can no 
longer be retracted back into the microcatheter).  Successful retraction is when 100% of 
the device is retracted without any foam tearing free 
16 Particulate generation # 0 0 = 
17 # of complete 
retractions into sheath 
after 90% deployed 
# 3 0 + 




# 3 1 = 















Method of Verification 
19 Tip deflection force gf 7 1 - Verify by measuring the force required to achieve 20° deflection of the distal edge of 
the NED when deployed in a microcatheter.  Measure the bending moment as: 
 
Mw = WLsinϴ 
 
Mw = actual bending moment at angle ϴ 
W =  total applied load (gf) 
L =  Length of pendulum arm (in.) 
ϴ =  Angle through which pendulum rotates 
 
Follow ASTM D747 Apparent Bending Modulus Test for guidance  
20 Shape memory 
recovery of foam 
% 95 80 + Verify by securing foam between two parallel plates in a calibrated rheometer and heat 
the temperature to Tg + 30°C and deform to 80% compressive strain at rate of 2.5 
mm/min.  Then cool foam to Tg - 20°C maintaining 80% strain.  Release strain at rate of 
2.5mm/min. and measure distance between plates at 10g axial force 
21 Shape recovery of 
foam 
kPa 700 0.05 + Verify by using a calibrated rheometer and run a dynamic temperature ramp test using a 
frequency of 1 Hz and heating rate of 1°C/min. from 25 to 50°C.  Use shear strain of 
0.2%.  Maintain torque of 0.5-5 g*cm 
 
22 Pressure required to 
deform primary coil 
shape 
kPa 700 0.05 + Verify by securing an actuated coil in its primary shape between parallel plate fixtures 
and ensure the force required to achieve 90% compression is above the stated lower 
limit 
23 Time to learn 
actuation method 
min. 5 0.5 - Verify the time it takes for an inexperienced interventional neuroradiologist to learn 
how to actuate the foam 
24 Actuation time min. 20 0.1 - Verify the time and temperature it takes for the foam to go from the crimped diameter to 
full expansion when tested in a simulated anatomical location at 37°C 25 Physiologically 
compatible 
temperature 
°C 50 37 - 
26 Range of device 
lengths 
cm 40 4 + Choose appropriate coil length and diameter based on angiographic results evaluating  
diameter, width, and height of aneurysm and width of aneurysm ostium 
27 Range of coiled 
diameters 
mm 20 3 + 
















Method of Verification 
Delivery Pusher & Detachment Mechanism (P&D) 
1 Radiopacity % 100 8 + Verify radiopacity by using appropriate medical imaging equipment and image the Pusher & 
Detachment (P&D) mechanism within a catheter and then compare to a metal guidewire.  
Use image capturing software to compare the contrast in pixel intensities between the 
background and the P&D, once complete compare the results between the background and a 
metal guidewire 
2 Outer diameter in. 0.020 0.010 - Verify with calibrated calipers to measure diameter 
3 Working length mm 200 150 + Verify with a tape measure to measure length 
4 Sharp edges or 
corners 
# 0 0 = Verify with visual inspection of P&D mechanism 
5 Advancement force gf 100 1 - Verify advancement force of the detachment mechanism does not exceed upper limit when 
tested in a simulated anatomical location at 37°C through a standard microcatheter and a 
hemostasis valve 
6 Retraction force gf 100 1 - Verify retraction force of the detachment mechanism does not exceed upper limit when 
tested in a simulated anatomical location at 37°C through a standard microcatheter and a 
hemostasis valve 
7 Prep time min. 5 0.5 - Verify the time it takes to prepare the detachment mechanism for placement into the catheter 
once it has been removed from its packaging 
8 Tensile strength of 
NED and 
Detachment zone 
gf inf. 150 +  
Verify by securing the NED wire backbone and the 
Pusher (attached to Detachment Mechanism) in a tensile 
testing machine and apply a tensile force, testing until 
failure to ensure the tensile strength is greater than the 
stated lower limit 
 
 
9 Tensile strength of 
Detachment zone 
and Delivery usher 
gf inf. 150 + 
10 Tip deflection force gf 7 1 - Verify by measuring the force required to achieve 20° deflection of the distal edge of the 
P&D when deployed in a microcatheter.  Measure the bending moment as: 
 
Mw = WLsinϴ 
 
Mw = actual bending moment at angle ϴ 
W =  total applied load (lbf) 
L =  Length of pendulum arm (in.) 
ϴ =  Angle through which pendulum rotates 
 





11 Buckling force gf inf. 150 +  
Verify by securing the distal end of the crimped foam in a 
fixture within a calibrated load cell and advance the P&D 
mechanism down a channel. Test until failure to ensure 






12 Detachment time s 5 0.5 - Verify the time it takes to completely detach the NED when tested in a simulated anatomical 
location at 37°C 
13 Reliability after 
fatigue  
cycles 30 6 + Verify the first fire detachment reliability is greater than 95% and second fire detachment 
reliability is 100% within the allotted detachment time following the stated number of 
deployment cycles.  Also verify there is no premature detachment caused by exposure to 
blood, body fluids, body temperatures, or repeated manipulation  
14 Time to learn how to 
detach NED 
Min. 5 0.5 - Verify the time it takes for an inexperienced interventional neuroradiologist to learn how to 
detach the NED from the detachment mechanism 
15 Exchanges through 
guiding catheter 
cycles 2 1 - Verify the NED can be delivered and detached in a simulated anatomical location at 37°C 
through a standard microcatheter without exceeding the upper limit of exchanges 
16 Length of external 
controller 
mm 120 75 + Verify with calibrated calipers to measure length 
17 Diameter of external 
controller 
mm 75 38 - Verify with calibrated calipers to measure diameter 
18 Weight of external 
controller 
lbs. 2 0.25 - Verify with calibrated scale to measure weight 







 Biocompatibility testing will need to be performed on the NED system per, “ISO 
10993-1 Biological Evaluation of Medical Devices – Part 1: Evaluation and Testing”.  
The NED is categorized per ISO 10993-1 as a permanent implant device that comes in 
contact with circulating blood (Table 20).  The delivery pusher and detachment 
mechanism are both categorized per ISO 10993-1 as external communicating devices in 
contact with circulating blood with limited contact duration (Table 21).   
 The SMP foam is a complex material that utilizes additives to control 
polymerization, processing, and stabilization.  Therefore, there will need to be material 
testing performed to determine the level of leachable substances and degradation 
byproducts.
45
  The biocompatibility evaluation is organized into eight categories of tests: 
“single dose toxicity, repeated dose toxicity, chronic toxicity, genotoxicity, 
carcinogenicity, reproductive toxicity, pharmacokinetics, and special toxicity”.
45
   
 Single dose studies are only administered to the test system within a 24-hour 
period so they would not apply to the NED system.  Repeated dose studies are used for 
multiple days of dosing and are appropriate for the NED system because of the long term 
contact with tissues.  A subacute or subchronic assay normally lasts less than 90 days, 
while chronic assays are normally exposures lasting beyond 10% of the lifespan of the 
test animal.  Genotoxicity assays focus on the effects of the SMP foam on the nucleic 
acids of the genes or chromosomes.  The FDA recommends a carcinogenicity study be 
conducted if a genotoxicity test result is positive.  The toxicity of the chemical 
components used in the synthesis of the SMP foam need to be considered when 
evaluating potential carcinogenicity.
44
  Reproductive toxicity assays determine the 
effects on the reproductive system.  Toxicokinetic assays consider the absorption, 
distribution, metabolism, and elimination of foreign chemicals like those identified in 
extraction studies.  Special toxicity assays commonly used on medical devices include 
immunotoxicity, hemocompatibility, and irritation.
45





 The NED system will need to meet strict pyrogenicity and sterility limits.  Since 
ethylene oxide (EtO) sterilization may cause neurotoxicity, the EtO residue levels will 
need to be measured along with obtaining biocompatibility information on the sterilized 
NED.  This information can be obtained by studying the tissue response after intracranial 
implantation.
44
  The NED system needs a sterility assurance level (SAL) of 1 x 10
-6
.   
The pyrogenicity needs to be evaluated and the amount of endotoxin allowed in the final, 
sterilized NED system should be less than 0.06 Endotoxin Units (EU)/ml.
44
   
 
Table 20. Biocompatibility Tests for the NED 
Test Description ISO 
Standard 
Cytotoxicity MEM Elution Test Evaluation  10993-5 
Sensitization Guinea pig maximization sensitization test with device extracts 




Intracutaneous reactivity test with device extracts (saline and 




Acute systemic toxicity test with device extracts (saline and 




In vivo Subacute Toxicity  
Material-Mediated 
Pyrogenicity 
Rabbit pyrogen test with saline extract of the device 10993-11 
Genotoxicity Bacterial Reverse Mutation Assay conducted with Device Extracts 
(Saline and PEG extracts) 
10993-3 
In Vitro Chromosomal Aberration Assay conducted with Device 
Extract (cell culture medium extract) 
10993-3 
Mouse Bone Marrow Micronucleus Assay conducted with saline 
extract of the device 
10993-3 
Implantation Evaluate in an animal bifurcate aneurysm model at 14 and 90 days  
Hemocompatibility In vitro hemocompatibility test with human blood and with saline 
extract of the device 
10993-4 
Direct contact hemolysis test using rabbit blood 10993-4 
Indirect contact (extract) hemolysis test with saline extract of the 












Table 21. Biocompatibility Tests for the P&D 
Test Description ISO 
Standard 
Cytotoxicity MEM Elution Test Evaluation  10993-5 
Sensitization Guinea pig maximization sensitization test with device extracts 




Intracutaneous reactivity test with device extracts (saline and 




Acute systemic toxicity test with device extracts (saline and 
cottonseed oil extracts) 
10993-11 
Hemolysis Indirect contact (extract) hemolysis test with saline extract of the 





UPTT test using human plasma and saline extract of the device 10993-4 
 
11.3 Validation  
  
 Once the verification tests are complete the NED system needs to be validated to 
prove by objective evidence that the user needs and intended use are consistently 
fulfilled. Validation is a pivotal step in completing the waterfall design process.  
Verification activities are completed to demonstrate the NED system performs according 
to the performance specifications.  Engineering methods are used to properly construct 
the performance specifications; however, the process is based largely on intuition and 
experience.  Thus, validation confirms that the specifications are correct and that the 
NED system properly occludes intracranial aneurysms.
3
   
 FDA recommends conducting pre-clinical animal studies to evaluate the NED 
system.  Initial validation efforts in the Biomedical Device Laboratory have used porcine 
models to assess biocompatibility and performance of the SMP foam-only plug.  The 
non-GLP study protocol, written by Julie Grinde at the Texas A&M Institute for 
Preclinical Studies, can be found in Appendix C.  Per the FDA “Class II Special 
Controls Guidance Document: Vascular and Neurovascular Embolization Devices”, 
study objectives in future animal trials will evaluate and validate the NED system based 







Table 22. NED System Validation 
FDA Guidance Document 
Recommendations 
Swine Bifurcate Aneurysm Study 
Objective 
Method of Validation 
Ease of delivery (friction and 
tortuosity) 
Demonstrate that the delivery and 
trackability of the NED is acceptable 
based upon subjective assessment of co-
investigator  
Evaluate fluoroscopic visualization, 
trackability, ease of advancing 
through the catheter, ease of 
aneurysm filling, ease of 
retrievability 
Acute complications (e.g. rupture or 
puncture of the blood vessels) 
Demonstrate that the acute (local and 
systemic) effects of the NED 
deployment are acceptable with regard 
to vessel perforation, life threatening 
alterations in vital signs, and any other 
notable events 
Ensure there is a 0% incidence rate 
of acute complications 
Recanalization of the 
vessels/durability of occlusion 
Demonstrate that the SMP foam can 
achieve aneurysm filling and occlusion 
results statistically comparable to 
literature reviewed results of Guglielmi 
detachable coils (GDC) using a similar 
model.  Occlusion results are measured 
by: 
 Volumetric filling of > 30% 
for each treated aneurysm 
based on angiographic 
calculation of aneurysm 
volume and calculation of 
SMP foam volume based on 
length used and volume 
expansion of SMP foam 
 Occlusion of 100% in > 30% 
of treated aneurysms on 
treatment day and on sacrifice 
(follow-up) day 
MRA or CTA may be performed in 
addition to standard digital 
subtraction and 3-D angiography to 
characterize chronic changes in 
aneurysm filling, including 
aneurysm exclusion, intraluminal 
thrombus formation, or distal 
emboli 
Local and systemic foreign body 
reactions 
Determine whether the acute (local and 
systemic) effects of SMP are acceptable 
via assessment based on angiographic 
evaluation for vessel perforation, life 
threatening alterations in vital signs and 
any other notable effects 
 
Determine the carotid tissue’s response 
to treatment with SMP based on 
evaluation of histopathology by the 
Study Pathologist 
 
Determine organ response to the SMP 
treatment based on evaluation of 
histopathology by the Study Pathologist 
 
Determine tungsten levels in the blood 
prior to and after implantation of the 
SMP foam at follow-up 
At necropsy, skin at body surfaces 
will be examined. 
 
Analysis will be performed from 
histological examination of the 
aneurysm sac, carotid arteries 
adjacent to aneurysm, and targeted 
vessels. 
 
Tissue from each group will be 
compared using the following 
factors: 
Degree of inflammation, fibrosis, 
tissue damage 
Extent and severity of damage will 
be compared within the group  
 
Histopathological evaluation will 
be conducted on lung, mediastinal 
lymph node, cervical lymph node, 
liver, spleen, adrenals, kidney, and 






FDA Guidance Document 
Recommendations 
Swine Bifurcate Aneurysm Study 
Objective 
Method of Validation 
Device migration The positional stability and aneurysm 
occlusion maintained through at least 6 
months of implant 
Digital subtraction and 3-D 
Angiography will be performed 
post SMP foam placement to 
document parent vessel integrity 
and check for any possible 
migration of the SMP foam.  MRA 
may be performed 
Embolization effectiveness Evaluate as % occlusion at follow-up Digital subtraction and 3-D 
Angiography will be performed 
post SMP foam placement to assess 





























12. AIM II: PROBLEM STATEMENT 
 
 The second specific aim is to develop performance specifications for SMP foam 
used in the development of a novel NED.  To achieve this aim, the chemicals used in the 
synthesis of the SMP foam are identified, activity diagrams are created, and performance 
specifications with verification tests are defined.      
 Part of the QSR is to have manufacturing controls in place to ensure a quality 
product can be produced consistently and reliably.  When establishing the quality control 
program, the first major hurdle was defining the performance specifications for the NED 
system.  The system was broken down into three distinct subsystems.  The NED 
subsystem was further broken down into the individual components that will be used.  
Of those components, SMP foam is the one that is developed in the Biomedical Device 
Laboratory, so it becomes the focus of attention.  It is, therefore, important to establish 
performance specifications that will be used to assess the quality of the SMP foam.   
 The performance specifications are completed with verification tests that will 
ultimately need to be validated in an animal study.  Once the specifications are defined, 
raw materials can be selected that best meet the specifications.  Before any process 
validation can occur it is important to understand what makes up the composition of the 
SMP foam.  The chemicals and associated toxicity data are identified.  Purification 
methods are suggested to help mitigate any biocompatibility issues and reduce the 
amount of impurities.   
  Activity diagrams are generated to provide a means of process mapping.  The 
activity diagrams help illustrate the various steps and components involved in the 











 13. PERFORMANCE SPECIFICATIONS 
 
13.1 Performance Specifications and Verification 
 
 Now that the performance specifications for the NED system are defined, it is 
important to focus on the development of the SMP foam and how it will affect the 
design.  Essential material properties of the SMP foam were identified by taking 
pertinent functional requirements from the NED HOQ.  These material properties will 
need to be monitored as to how well they meet the NED performance specifications.  
The vital requirements at the subsystem level were used as inputs to determine the vital 
material properties at the component level.  Target values were then assigned to the 
appropriate material property.  A lower and upper limit for the target values along with 
an ideal direction was defined.  The ideal direction provides guidance about whether the 
design should strive to achieve the upper or lower limit. 
 Once the target values are chosen, the performance specifications need to be 
verified. Tests needed to be written to provide an objective method of analysis to prove 
each specification falls within the established limits. The design output for this stage of 
development is the result of each verification test.  The performance specifications and 
verification tests have the method for the test as well as the acceptance criteria (Table 


















Method of Verification 
1 Filling percentage Shape memory 
recovery 
% 98 80 + Verify by securing foam between two parallel plates in a rheometer and 
heat the temperature to Tg + 30°C and deform to 80% compressive strain 
at rate of 2.5 mm/min.  Then cool sample to Tg - 20°C maintaining 80% 
strain.  Release strain at rate of 2.5mm/min. and measure distance 
between plates at 10g axial force.46 
2 Volume 
expansion 
% 7000 5000 + Verify by first measuring the crimped diameter with calibrated caliper 
gauge then actuate the foam and measure the expanded foam with same 
calibrated caliper gauge.  Calculate net volume expansion (ignoring 
change in length) as follows: 
 
Volume expansion = (recovered diameter / compressed diameter)2 
3 Crimped diameter 
 
Density g/cm3 0.025 0.015 - Verify by following Test A – Density Test as defined in ASTM D3574.  
Calculate density based on equation: 
 
Density = M/V x 106 
 
M = mass of specimen in grams 
V = volume of specimen in mm3 
4 Cell 
morphology 
% Open Closed + Verify by visual inspection under a microscope 
5 Cell size µm 500 100  + Verify by measuring the polar diameter (parallel to direction of foam 
rise) and equatorial diameter (perpendicular to direction of foam rise) 







°C 70 45  - Verify by using Differential Scanning Calorimetry.  Cool sample to -
40°C and then run through a heat-cool-heat cycle from -40 to 120°C.  
The half-height of transition during second heat can be taken to estimate 
Tg.
46  
7 ΔTg of foam °C 20 1 - Verify by using a rheometer and run a dynamic temperature ramp test at 
a frequency of 1 Hz and constant heating rate of 1°C/min. from 25 to 
50°C.  Use an initial shear strain of 0.2%.  As temperature increases 
maintain torque range of 0.5-5 g/cm 
 
ΔTg (breadth of transition = 2(Tδs – Tonset).
46 
 
8 Shape recovery  Rubbery storage 
modulus 
(G’rubbery) 
kPa 15 5 + 
9 Glassy storage 
modulus 
(G’glassy) 






14. ACCEPTANCE ACTIVITIES 
 
14.1 Identification of Chemicals 
 
 A component, as defined in 820.3(c) of the QSR, is any material or substance 
that will be included in the finished NED.
30
  Since the SMP foam is not a FDA approved 
material it will be the component that is the primary point of concern for getting the 
NED cleared or approved.   
 A way to mitigate uncertainty the FDA may have with the NED, is to list the 
chemicals used in the synthesis of the SMP foam.  Per the FDA’s, “Class II Special 
Controls Guidance Document: Vascular and Neurovascular Embolization Devices”, the 
raw materials and reagents used to synthesize the SMP foam were identified (Table 24).   
 
Table 24.  SMP Foam Chemicals Used 
Chemicals CAS Vendor  Part # Chemical Contents 
Hexamethylene Diisocyanate 
1,6 diisocyanatohexane (HDI)  
822-06-
0 
TCI America H0324 C8H12N2O2 
N,N,N’,N’-Tetrakis(2-hydroxypropyl 
ethylenediamine) (HPED)  
102-60-
3 
TCI America T0781 [CH2N(C3H6OH)2]2 
Triethanolamine  
2,2’,2”-Nitrilotriethanol (TEA)  
102-71-
6 
Sigma Aldrich 90278 C6H15NO3 
RO water N/A Texas A&M  N/A H2O 
Dabco BL-22 Catalyst  112-18-
5 
Air Products BL-22 C14H31N 
Dabco T-131 Catalyst  N/A Air Products T-131 C-Sn (Organotin) 
Dabco DC1990 Surfactant 6430-
39-3 
Air Products Dabco 
DC1990 
Trade secret – siloxanes and 
silicones 
Dabco DC5179 Surfactant  N/A Air Products Dabco 
DC5179 
Trade secret 
Tungsten Powder  7440-
33-7 





Hydrochloric acid solution, 1.0  7647-
01-0 
VWR BDH3202-1 HCl 











 The FDA also recommends identifying any reagent that is potentially toxic.  
Thus, material safety data sheets (MSDS) were consulted to obtain toxicological 
information about each chemical (Table 25).   
 The LD50 value stands for lethal dose and represents the quantity of material that 
will cause 50% of the animal subjects to perish.  A large LD50 value means it takes a 
large amount of that material to be a health hazard.  The toxicity units are expressed in 
the amount of material per kilogram of subject-body-weight.     
 
Table 25. SMP Foam Chemicals’ Toxicological Information 
Chemicals Toxicological Information 
Hexamethylene Diisocyanate 
1,6 diisocyanatohexane (HDI)  
Rat LD50 (oral) 710 µL/kg 
Rat LC50 (inhalation) 124 mg/m
3/4H 
Rabbit LD50 (skin) 570 µL/kg 
Skin irritation Severe 
Eye irritation Severe 
Carcinogenic effects No data available 
Mutagenic effects No data available 
Teratogenic effects No data available 
Developmental 
toxicity 
No data available 
N,N,N’,N’-Tetrakis(2-hydroxypropyl 
ethylenediamine) (HPED)  
Rat LD50 (oral) 500 mg/kg 
Man LD50 (unknown) 3900 mg/kg 
Skin irritation No data available 
Eye irritation No data available 
Carcinogenic effects No data available 
Mutagenic effects No data available 
Teratogenic effects No data available 
Developmental 
toxicity 
No data available 
Triethanolamine  
2,2’,2”-Nitrilotriethanol (TEA)  
Rat LD50 (oral) 5,530 mg/kg 




Skin irritation May be harmful 
Eye irritation May cause irritation 
Respiratory 
sensitization 
No data available 
Germ cell 
mutagenicity 
No data available 
Carcinogenic effects No data available 
Reproductive effects No data available 
Teratogenic effects No data available 
RO water N/A 
Dabco BL-22 Catalyst Rat LD50 (ingestion) >1,630 mg/kg 
Rat LC50 (inhalation) >580 mg/l 
Rabbit LD50 (skin) 280 mg/kg 








Chemicals Toxicological Information 
Dabco T-131 Catalyst Rat LD50 (ingestion) 510 mg/kg 
LC50 (inhalation) No data available 
Rabbit LD50 (skin) >2,000 mg/kg 
Eye irritation severe 
Skin irritation Severe 
Dabco DC1990 Rat LD50 (ingestion) 2,550 mg/kg 
Inhalation No data available 




Dabco DC5179 Surfactant  Ingestion  No data available 
Inhalation No data available 
Skin No data available 
Eye irritation No data available 
Tungsten Powder  Skin irritation Irritant to skin and mucous 
membranes 
Eye irritation Irritating effect 
Chronic exposure May result in permanent lung damage 
Carcinogenic effects No data available 
Enovate 3000 Rat LC50 (inhalation) >200,000 ppm 
Rat LD50 (skin) >2,000 mg/kg 
Teratogenic effects Not a teratogen 




Ingestion irritation May cause burns to mouth, throat, 
and stomach 
Inhalation irritation Irritating to respiratory system 
Skin irritation Corrosive 
Eye irritation Corrosive 
Carcinogenic effects No known significant effects 
Mutagenic effects No known significant effects 
Teratogenic effects No known significant effects 
Contrad 70  Inhalation May cause respiratory irritation 
Skin irritation May cause reddening and irritation 
Eye irritation May cause irritation and damage 
















14.2 Purification Methods for Chemicals  
 
 When synthesizing the SMP foam it is desirable to start with chemicals that have 
the highest purity level commercially available.  However, even when selecting the 
highest grade chemical, there still may be unspecified impurities present.  A 
‘manufacturing material’, as defined in 820.3(p) of the QSR, is any material or substance 
used in or produced during manufacturing which is on or in the processed NED as a 
residue or impurity.
30
  Therefore, it becomes important to establish methods to further 
purify the chemicals.  Considering purity has different levels, the objective is to reduce 
the impurities as much as necessary.  There are various ways to assess the degree of 
purity.  Physical properties can be examined such as density, optical rotation, and 
refractive index at a specified wavelength and temperature.  Physical tests can be 
performed such as emission and atomic absorption spectroscopy, chromatography, X-ray 
or mass spectroscopy and electron spin resonance.  Spectroscopic properties can also be 
examined such as infrared spectroscopy, nuclear magnetic resonance, and ultraviolet 
spectroscopy.
47
   
 Ultimately, the right amount of purification will need to be verified in the 
biocompatibility tests and validated when the NED is implanted during an animal study.  
An initial draft of purity information and suggested methods for further purification was 
written (Table 26).  Certificates of Analysis (CoA) for each chemical were studied to 

















Table 26. SMP Foam Chemicals’ Purification Methods 
Chemicals Purity (%) Chemical 
Analysis 
















Fractional distillation under nitrogen to prevent reaction 








98 Visual React aqueous ammonia with ethylene oxide in the liquid 
phase at elevated temperature and under pressure. 
Remove excess ammonia, water and monoethanolamine 
from the reaction product.  React the resulting crude 
product with ethylene oxide at temperatures of 110 to 180 
C., and then rectify the mixture in the presence of 












RO water N/A N/A Distillation 







Dabco T-131 Catalyst N/A N/A 
Dabco DC1990 
Surfactant 
N/A Appearance Mix surfactant with 1/1 ratio of water and oil in a flask 
and place in waterbath. Stir solution until equilibration 
then remove oil-phase containing most of the oleophilic 
impurities.  Add back as much pure oil as was removed.  
Adjust waterbath to new temperature and stir solution 
again.  After equilibration and phase separation, remove 
the waterphase containing most of the hydrophilic 
impurities.  Add back as much pure water as was 
removed and repeat the process 4-6 times. Concentrate 
surfactant by distilling remaining oil and water under 






Tungsten Powder 100 Not listed Clean with concentrated NaOH solution.  Wash with 
boiled and cooled conductivity water and dry on filter 
paper.47 
Enovate 3000 99.9 Assay Distillation50 
Water 
Hydrochloric acid 
solution, 1.0 N  
0.1004 
Normality 
Appearance Fractional distillation as constant boiling point acid, and 
then dilute with H2O.
47 
Contrad 70 N/A N/A Add slight excess of saturated BaCl2 or Ba(OH)2 to the 









14.3 Activity Diagrams 
 
 Activity diagrams were used to illustrate the procedures of synthesis and post 
synthesis processing of the SMP foam.  The synthesis of the SMP foam was broken 
down into the preparation of two separate premixes used in the foam, as well as the post 
synthesis activities of annealing, etching, and cleaning (Fig. 9).  
 The first premix, isocyanate pre-polymer containing nitrogen, carbon, and 
oxygen (NCO), is used to optimize the rheology of the system of monomers during the 
foaming reaction to facilitate the creation of low density foams.  The preparation of 
NCO can be found in Appendix D in Figure 10.  The second premix, a hydroxyl 
monomer (OH), is prepared to create a uniform liquid mixture of as many of the 
remaining foam components as possible.  The OH premix is then added to the NCO 
premix during the foaming reaction.  Preparing the premixes beforehand ensures both 
better mixing of each premix and also a more consistent composition from one batch of 
foam to the next.  The preparation of OH can be found in Appendix D in Figure 11. 
 Post synthesis activities begin with annealing the foam under vacuum.  
Annealing removes residual volatile components and completes the reaction of residual 
isocyanate.  The annealing process can be found in Appendix D in Figure 12.  
Mechanical processing by compression and expansion of the SMP foam, fractures 
residual cell membranes to facilitate better etching and cell membrane removal.  The 
mechanical processing can be found in Appendix D in Figure 13.  Etching the foam 
removes residual mobile species and also removes cell membranes to open cells.  
Cleaning the foam further removes debris and any possible biological material that the 
foams were exposed to during synthesis.  The etching and cleaning process can be found 













 The design research performed has the objective of aiding in the development of 
a NED system for occluding intracranial aneurysms.  If left untreated, ruptured 
intracranial aneurysms can lead to devastating consequences.  Current treatment options, 
offered through a minimally invasive endovascular approach, only occlude 
approximately 30% of the aneurysm which can lead to recanalization and re-bleeding.  
Therefore, it is imperative to develop devices that can achieve higher occlusion rates.  
The Biomedical Device Laboratory, led by Dr. Maitland, is developing an NED system 
made out of SMP foam.  The shape memory characteristic of the SMP will give the NED 
an ability to be compressed down into a compact size for delivery via a catheter.  Once 
in place the device can be induced to regain its complex, primary shape and expand up to 
70x for superior occlusion of aneurysms. 
 The first specific aim focused on the front-end of the product development 
process.  Customer needs were generated from interviews, activity diagrams, and market 
research.  Functional models were used to define the function and various sub-functions 
of the NED system and to ensure the design inputs follow the user needs.  Benchmarking 
was conducted to help clarify user requirements and understand current market products 
and technology trends.  The customer needs were then translated into quantifiable 
engineering requirements. A HOQ matrix was used to map the customer needs to the 
engineering requirements and help elucidate the relationships between the needs and the 
requirements and between the requirements themselves.  Acceptance criteria were 
established with an ideal direction for the design to achieve. An FMEA was performed 
to highlight possible design deficiencies as a way of mitigating future risk.  The 
performance specifications for the NED system were defined with verification tests for 
each requirement.  Verification of the NED system must consist of determination 
through documented testing that each subsystem will reliably perform its function under 
the most adverse environmental conditions in which they will be used.   





 The second specific aim focused on the initial concerns of establishing 
manufacturing controls for the synthesis of the SMP foam.  The performance 
specifications for the NED system were used to identify vital material properties of the 
SMP foam that will have an impact on the device design.  Each chemical that goes into 
synthesizing the SMP foam was listed along with the toxicological information.  When 
synthesizing the SMP foam it is important for the chemicals to have the highest purity 
level commercially available.  Therefore, an initial draft of purity information and 
methods for further purification was suggested.  Activity diagrams were then used to 
illustrate the procedures of synthesis and post synthesis processing of the SMP foam. 
 Further work into the design of the NED system will inevitably result in new 
performance specifications.  All the design documentation will need to be reviewed and 
updated as new information about the NED system becomes available.  The waterfall 
design process, though, is structured for changes and improvements to be incorporated 
back into the design effort.  It is an iterative process that can be adapted and tweaked as 
necessary.  Any changes will need to go through verification and ultimately validation to 
ensure the redesigned NED system meets the needs of the user and is safe and effective 
at treating intracranial aneurysms.   
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APPENDIX A  
 
CUSTOMER NEEDS ASSESSMENTS 
 
Table 27. Customer Needs Assessment from Market Research of Doctors’ Opinions on Current FDA Cleared Devices 
Date: February 
15-17, 2012 
Market Research  Neurovascular Embolization Device (NED)  
Category End User Customer Statement Interpreted Need Importance 
Rating 
Ease of Use 
Dr. David Kallmes - Mayo 
Clinic, Rochester MN 
Device is easily guided, positioned and repositioned, 
and released through standard microcatheters  




The NED can be retracted back into the 
micro-catheter and repositioned after partial 
deployment at least once.   
5 
Dr. Michael Horowitz - 
University of Pittsburgh 
Medical Center 
Coils deliver with minimal resistance or snaking 
through 0.021" microcatheters 
The NED is easily pushed and pulled 
through the microcatheter 
5 
Dr. Michael Horowitz - 
University of Pittsburgh 
Medical Center 
Ability to fill interstices is exceptional 
The NED will use fewer coils to provide 
superior embolization of the aneurysm over 
time compared to current devices 
4 
Detachment 
Dr. W.J. van Rooij - The 
Netherlands 
Coils went in smoothly and detached immediately 
The NED has Detachment that is immediate 
and reliable 
5 
Dr. Demetrius Lopes - 
Neurosurgical Orthopedic 
Hospital, Chicago IL 
Complexity of case required fast and reliable 
detachment of coils, may decrease length of case and 
complications from poor detachment 
Dr. Michael Horowitz - 
University of Pittsburgh 
Medical Center 
New release system makes procedures simpler and 
quicker by providing instantaneous coil deployment, 
obviating need for cables, boxes, and batteries 
Actuation 
Dr. Behrat Mehta - Henry 
Ford Hospital, Detroit MI 
Angiographic occlusion of the aneurysm was 
achieved without neck remnant 













Table 28. Customer Needs Assessment from Interview with Ms. Grinde 
Date: April 
5, 2012 
Interviewee: Julie Grinde 
Job Title:  Research Associate 
Texas A&M University 
Neurovascular Embolization Device 
(NED) 
 
Category Customer Statement Interpreted Need Importance 
Rating 
Ease of Use 
Will want some kind of radiopaque marker so 
physician will know when the device is no 
longer retractable 




Important to minimize friction, want 1:1 
movement to ensure predictability of where 
coil is positioned within microcatheter 
The NED is easily pushed and 
pulled through the microcatheter 
5 
Might consider deep positioning of catheter to 
enable sideways coiling of device for better 
neck coverage 
The NED can withstand being 
twisted and bent 
5 
Matrix coating broke down too quickly, led to 
loss in volume and compaction 
The NED uses fewer coils to 
provide superior embolization of 
the aneurysm over time compared 
to current devices 
4 
Between 8-20 coils are used to occlude larger 
aneurysms 
Matrix compared performance to GDCs 
Similarity to prior technology and 
ease of use are definitely a plus in 
terms of adoption 
4 
Pusher 
When retracting device could run into 
problems with multiple foam pieces on wire.  
Want to eliminate stutter when retracting.  
Foam pieces might catch on catheter during 
retraction 
The NED can be retracted back into 
the sheath and repositioned after 
partial deployment at least once 
5 
GDC and Matrix coils could be 100% out of 
the catheter and still be retracted.  Sometimes 
it does happen in clinical setting that device is 
retracted after being fully deployed 
Device should be able to be retracted 2-3 times 
The NED can be retracted and 
repositioned 2-3 times is preferred 
3 
Detachment 
Matrix Detachment System took too long, 30-
60s.  Micrus had immediate detachment 
The NED has Detachment that is 
immediate and reliable 
5 
Want to limit catheter movement, painting.  
Some doctors don’t mind catheter movement, 
helps them locate the device 
The NED has Detachment that does 
not alter the position of the 
microcatheter during positioning, 
detachment, and actuation 
5 
Actuation 
Want uniform shape 
The NED actuates into stable, 
known configuration and diameter 
5 
Matrix had stiff detachment zone which 
created a tail that stuck out into the parent 
vessel 
Matrix had no expansion so you know exactly 
where coil will be positioned 
Main point to coiling is covering the neck of 
the aneurysm.  Coverage across the neck is an 
important parameter 
The NED actuates to cover the neck 
of the aneurysm 
4 
Dome is the thinnest part of the aneurysm, 
want to make sure foam expansion doesn’t 
rupture the aneurysm 




Hospitals have limited storage for quantities of 
coils.  Need to determine right sizes and 
shapes to treat majority of aneurysms 
The NED is manufactured with 






Table 29. Customer Needs Assessment from Market Research of Marketing Literature on Current FDA Cleared Devices 
Date: February 15-
17, 2012 
Market Research Neurovascular Embolization Device (NED)  
Category Customer Statement Interpreted Need Importance 
Rating 
Ease of Use 
Enhanced trackability through microcatheter The NED will be visible under fluoroscopy during implantation 5 
Smooth movement through microcatheter 
The NED is easily pushed and pulled through the microcatheter 5 Smoother coil positioning 
Remove coil if unusual friction or "scratching" is noted 
Safety and handling characteristics equivalent to existing 
products 
The NED behaves and actuates similarly to predicate devices 4 
Balance of softness, stability, and volume through entire 
coil line 
Softest coil ever - unites finishing-coil softness with Gold 
Standard in shape 
Three grades of softness for progressive coil compliance 
Minimized set-up time with simple sheath system 
The NED is ready to use right out of the package 3 
No prep, no steaming 
Pusher 
Responsive placement and repositioning 
The NED Delivery Pusher does not alter the position of the 
microcatheter during positioning, detachment, and actuation 
5 
New, more flexible delivery pusher minimizes catheter 
movement 
Pushability and flexibility, new level of tactile sensation 
Soft gripper tube results in minimal catheter tip deflection 
while coiling.  Stable coil delivery 
Balanced stiffness zones provide flexibility and pushability 
yield one-to-one feel 




No movement of coil after coil placement or prior to 
detachment 
The NED had Detachment that does not alter the position of the 
microcatheter during positioning, detachment, and actuation 
5 
Soft floating detachment link minimizes catheter kick out 
Softer, shorter junction to minimize kickback for increased 
control and stability 
Softer, shorter detachment zone reduces microcatheter 
deflection, increases coil placement ability 
Minimal migration The NED will remain in the aneurysm once detached 5 
Fast detachments and real-time feedback with a single click 
The NED has detachment that is immediate and reliable 5 Velocity you appreciate, simplicity required 
Fast detachments with no compromise to tensile strength 
Actuation 
Designed to resist deformation from hemodynamic forces 
with aim to retain original shape 





Stability with coil frame, microcatheter position & 
improved neck coverage 
The NED actuates into stable, known configuration and diameter 5 
Loop to length ratio enhances biomechanical stability 
Improved stability upon marker alignment 
Coil coverage across neck 
The NED actuates to cover the neck of the aneurysm 4 
Conformability and neck-to-dome stability 
First or second coils should NEVER be less than width of 
neck (ostium) 
Variable diameter loops provide optimum framing 
First two loops smaller allow for more controlled 
deployment 
Two initial helical loops help anchor the coil within the 
aneurysm 
First 1.5 loops 25% smaller than stated secondary coil 
diameter to reduce coil herniation 
Tight loops form a mechanically interconnected structure 
to resist compaction 
Initial loop sizes to aneurysm, mitigating risk prolapse into 
parent vessel 
Frames from outside in, utilizes inner coil loops to provide 
optimal bracing for frame support 
Open loops for conformance to shapes while minimizing 
compartmentalization 
Without assuming pre-determined 3D shape can frame 
many morphologies The NED can conform to range of shapes 3 
Treats range of shapes - spherical to multi-lobed 










End User: Dr. Matthew Miller 
Job Title: Professor of Cardiology 
Department of Small Animal Medicine and 
Surgery 
College of Veterinary Medicine, Texas A&M 
University 
Neurovascular Embolization Device 
(NED) 
 
Category Customer Statement Interpreted Need 
Importance 
Rating 
Ease of Use 
Want maneuverability and flexibility The NED can withstand being 
twisted and bent 
5 
Want it to feel secure enough 
If the working time is only 5-10 minutes per 
coil, there is added pressure of implanting 
within a short time window 
15 minutes may be better, but 20 minutes is a 
long time especially if there are multiple 
coils to place 
The NED has a working time of 10-




There are severe issues and limitations if not 
retractable 
The NED can be retracted back into 
the sheath and repositioned after 
partial deployment at least once 
5 
Problems arise with too much reworking and 
repositioning including damage to the 
endothelium and possibly bursting the 
aneurysm 
The NED has a Detachment that is 
immediate and reliable 
5 
The NED has a simple, user-
controllable Detachment 
4 
Pieces of foam do not break off 
The NED does not have foam pieces 
break off when retracted 
5 
Provide a failsafe that the device can always 
be pulled back into guiding catheter. Possible 
to remove entire system from body and try 
new implant if necessary 
The NED can be retracted back into 
the microcatheter after partial 
deployment at least once with the 
NED in any configuration 
5 
Would be ideal if it was always retractable, 
practical need is that it is retractable at least 
once 
The NED can be retracted and 
repositioned 2-3 times is preferred 
3 
Detachment 
Deploying will not alter shape or stiffness of 
catheter 
The NED does not alter the position 
of the microcatheter during 




Do not want the coil to protrude out of the 
aneurysm 
Do not compromise the parent vessel 
The NED actuates into known 
configuration and diameter 
5 
Size to maximal diameter 
If undersized relative to aneurysm could have 
a ball of foam bouncing around 
The NED will remain in the 
aneurysm once detached 
5 
Without actuation, how will the coil stay in 
place? 
Too many exchanges through the catheter 
could cause problems 
The NED has few number of 
exchanges through the guiding 
catheter  
3 
Infinite working time may not be optimal, it 
can lead to complications 
The NED has active user-controllable 
actuation 
2 Light actuation is the most interesting 
Chemical actuation is normally 
biocompatible but not as controllable 
Size 
Want a wide variety of different lengths, 
diameters, and number of revolutions 
available 
The NED is manufactured with 






Table 31. Customer Needs Assessment from Observation of Clot Extraction Procedure 
Date: August 5, 
2011 





End User:  Dr. Andrew Xavier 
Job Title: Interventional Neuroradiologist 
St. Joseph Mercy Oakland  
Stroke Center 
Neurovascular Embolization Device 
(NED) 
 
Category Observations Interpreted Need Importance 
Rating 
Ease of Use 
Each stent was in the microcatheter from 2-
10 minutes 
The NED has a working time of 10-
15 minutes once placed in the 
microcatheter 
5 
The neurovasculature was tortuous, with 
multiple bends and odd angles 
The NED can withstand being 
twisted and bent 
5 
Once the catheter was opened from the 
package, it was placed in a saline bath and 
left there until needed 
The NED can withstand 6 hrs. 




The stent was retracted once before being 
properly placed 
The NED can be retracted back into 
the sheath and repositioned after 
partial deployment at least once 
5 
There were two separate attempts at 
implanting the stent.  The stent was 
completely removed from the body before 
another attempt was made 
The NED can be retracted back into 
the microcatheter after partial 
deployment at least once with the 
NED in any configuration 
5 
The reperfusion catheter and stent were 
repositioned multiple times before the 
doctors were satisfied with the placement 
The NED has a Delivery Pusher that 
does not alter the position of the 
microcatheter during positioning, 
detachment, and actuation 
5 
The NED can be retracted and 
repositioned 2-3 times is preferred 
3 
Detachment 
The doctors instructed the nurses to turn 
the Penumbra pump on while keeping their 
eyes on the imaging screens and controlling 
the reperfusion catheter 
The NED has a simple, user-
controllable Detachment 
4 
Multiple nurses were switching the 
Penumbra system on and off, depending on 
who was near the pump 
Actuation 
The doctors had the Penumbra turned on 
and off multiple times while they were 
positioning the reperfusion catheter 




The doctors used a wide variety of different 
sized catheters 
The NED is manufactured with 






APPENDIX B  
 
ADVERSE EVENTS FROM MAUDE 
 
Table 32. Adverse Events Reported for the NED 
# Company Trade Name Event Type Adverse Event Description Manufacturer Narrative Date  
1 Codman Neurovascular TRUFILL DCS Orbit 
Detachable Coil 
System 
Malfunction Difficult to advance due to 
resistance/friction 
During repositioning, coil stretched  
Additional information will be submitted 
w/in 30 days  
3/30/2012 
2 Codman Neurovascular TRUFILL DCS Orbit 
Detachable Coil 
System 
Injury Coil stretched during placement, broke 
during withdrawal. Coil and part of 
microcatheter containing coil 
remained in patient’s body 
Additional information will be submitted 
w/in 30 days 
3/27/2012 
3 Micrus Endovascular PRESIDIO 
Microcoils 
Injury Physician experienced “unraveled 
feeling”, coil came off at detachment 
zone 
Additional information will be submitted 
w/in 30 days 
3/26/2012 
4 Stryker Neurovascular GDC 360° Detachable 
Coils 
Malfunction Radiopaque markers were not visible N/A 3/26/2012 
5 Micrus Endovascular DELTAPLUSH 
Microcoils 
Malfunction Coil got entangled while pulling back 
into microcatheter during preparation 
Additional information will be submitted 
w/in 30 days 
3/26/2012 
6 Micrus Endovascular MICRUSPHERE 
Microcoil 
Malfunction Quality inspection noticed device was 
unpacked and lost its sterility 
Additional information will be submitted 
w/in 30 days 
3/26/2012 
7 Stryker Neurovascular GDC 360° Detachable 
Coils 
Injury During withdrawal resistance was 
encountered, coil stretched and broke 
from delivery wire and protruded from 
aneurysm 
N/A 3/26/2012 
8 Codman Neurovascular TRUFILL DCS Orbit 
Detachable Coil 
System 
Injury Coil got stuck in microcatheter 
Delivery pusher kinked/bent 
Thrombus in microcatheter may have 
caused adherence 
Additional information will be submitted 
w/in 30 days 
3/23/2012 
9 Codman Neurovascular TRUFILL DCS Orbit 
Detachable Coil 
System 
Malfunction During repositioning, coil stretched Additional information will be submitted 
w/in 30 days 
3/23/2012 
10 Covidien AXIUM Detachable 
Coils 
Injury Aneurysm ruptured Device not returned for evaluation 3/22/2012 
11 Codman Neurovascular TRUFILL DCS Orbit 
Detachable Coil 
System 
Injury Patient complained of abducens 
paralysis 





# Company Trade Name Event Type Adverse Event Description Manufacturer Narrative Date  
12 Codman Neurovascular TRUFILL DCS Orbit 
Detachable Coil 
System 
Malfunction During withdrawal, coil detached from 
gripper at coil detachment point 
Additional information will be submitted 
w/in 30 days 
3/22/2012 
13 Codman Neurovascular TRUFILL DCS Orbit 
Detachable Coil 
System 
Malfunction Coil stretch and could not be used Lot inspection did not reveal any 
discrepancies 
3/21/2012 
14 Codman Neurovascular TRUFILL DCS Orbit 
Detachable Coil 
System 
Malfunction During repositioning, coil stretched Additional information will be submitted 
w/in 30 days 
3/21/2012 
15 Micrus Endovascular PRESIDIO 
Microcoils 
Malfunction During repositioning, coil stretched Additional information will be submitted 
w/in 30 days 
3/20/2012 
16 Micrus Endovascular CASHMERE 
Microcoils 
Malfunction During withdrawal, coil unraveled in 
microcatheter 
Additional information will be submitted 
w/in 30 days 
3/20/2012 
17 Micrus Endovascular CASHMERE 
Microcoils 
Malfunction During repositioning, coil stretched Additional information will be submitted 
w/in 30 days 
3/20/2012 
18 Codman Neurovascular TRUFILL DCS Orbit 
Detachable Coil 
System 
Malfunction Coil stretch and could not be used Additional information will be submitted 
w/in 30 days 
3/19/2012 
19 Stryker Neurovascular Target Detachable 
Coils 
Malfunction After implanting, small part of coil 
was protruding into parent vessel 
Operational context is most likely cause 
of event 
3/16/2012 
20 Stryker Neurovascular Target Detachable 
Coils 
Malfunction During withdrawal, coil detached 
within the microcatheter 
N/A 3/15/2012 
21 Stryker Neurovascular Target Detachable 
Coils 
Malfunction During unpacking, proximal end of 
delivery wire broke 
N/A 3/14/2012 
22 Stryker Neurovascular Target Detachable 
Coils 
Injury During delivery, some resistance was 
encountered. Aneurysm ruptured 
Operational context is most likely cause 
of event 
3/13/2012 
23 Codman Neurovascular TRUFILL DCS Orbit 
Detachable Coil 
System 
Malfunction Coil delivery system was difficult to 
move out of coil introducer 
During prep, coil stretched 
Additional information will be submitted 
w/in 30 days 
3/12/2012 
24 Codman Neurovascular TRUFILL DCS Orbit 
Detachable Coil 
System 
Death During delivery, coil prematurely 
detached 1/3 of the way through mc, 
also stretched.  Coil protruded from 
aneurysm 
Based on the available information no 
conclusion can be made regarding the 
reported stretching & premature 
detachment of the orbit coil prior to 
exiting the microcatheter 
3/6/2012 
25 Penumbra Inc. Penumbra Coil 400 Injury During withdrawal, coil broke and 
protruded from aneurysm 
Without the return of the device, the root 
cause of the issue cannot be determined 
3/6/2012 
26 Stryker Neurovascular Target Detachable 
Coils 
Injury During implanting, coil dislodged 
from aneurysm and migrated into 
artery 









# Company Trade Name Event Type Adverse Event Description Manufacturer Narrative Date  
27 Micrus Endovascular Micrus Microcoil 
System 
Injury After implanting, coil broke free and 
protruded from aneurysm ,causing 
stroke 
Without the return of the device, the 
exact root cause of the problem reported 
could not be determined 
2/29/2012 
28 Penumbra Inc. Penumbra Coil 400 Injury Intracranial hemorrhage with definite 
relationship to the penumbra coil 
system 
Determined that the reported event was 
an anticipated procedural complication. 
2/28/2012 
29 Codman Neurovascular TRUFILL DCS Orbit 
Detachable Coil 
System 
Malfunction Coil auto-released in microcatheter Additional information will be submitted 
within 30 days of receipt 
 
2/24/2012 
30 Codman Neurovascular Orbit GALAXY 
Detachable Coil 
System 
Malfunction After implanting, coil did not seek 
perimeter of aneurysm instead 
compartmentalized 
Additional information will be submitted 
within 30 days of receipt 
 
2/23/2012 





Table 33. Adverse Events Reported for the Delivery Pusher 







Malfunction Physician made kink in 
pusher wire, bent it straight, 
then wire broke immediately 





Injury Detached prematurely inside 
microcatheter 






Malfunction Coil detached from pusher 
wire 







Malfunction During withdrawal, blue 
stopper/introducer became 
dislodged/separated  
Additional information will be submitted w/in 30 days 3/20/2012 
5 Penumbra Inc. Penumbra Coil 
400 
Injury During repositioning, lost 
control of coil which was no 
longer attached to the pusher 
If the tip of the microcatheter was pressed tight against the wall of 
the aneurysm, a sharp angle between the coil and the tip of the 
catheter would be created. The angle may have caused the distal 
detachment tip of the pusher assembly to catch on the tip of the 
catheter when the catheter was advanced over the pusher assembly 
and coil during repositioning as described in the complaint. This 
may have resulted in stretching the flexible tip of the pusher 
assembly just enough to relax the pre-compression in the pull wire 







Malfunction Coil was not attached to 
delivery wire 
Not soaking the coil in saline resulted in difficulties, coil was 








Malfunction During withdrawal, coil 
could not be re-sheathed and 
was kinked 
Cause of the reported event and damages found on the unit cannot 
be conclusively determined 
3/5/2012 
8 Penumbra Inc. Penumbra Coil 
400 
Injury During repositioning, coil 
protruded out of aneurysm 
and became stuck and broke 
from pusher 
Without the return of the device, the root cause of the problem 
cannot be determined 
3/2/2012 
9 Penumbra Inc. Penumbra Coil 
400 
Injury During repositioning, coil 
detached and protruded from 
aneurysm 
Returned condition of the device is not consistent with the event 






Table 34. Adverse Events Reported for the Detachment Mechanism 






Injury Ready light did not illuminate 
Could not detach 1st coil, problem with 1st 
cable 
Additional information will be 







Malfunction Could not detach coil Product not returned. Lot 





PRESIDIO Microcoils Malfunction Ready light did not illuminate 
Could not detach 1st coil, other coils detached 
with same cable 
Additional information will be 






Malfunction 2 syringes used but could not detach coils Additional information will be 







Injury Coil would not detach 
While repositioning the coil accidently 
detached 
Additional information will be 














Malfunction Coil failed to detach Additional information will be 






Malfunction 2 syringes used but could not detach coils 
During withdrawal, coil delivery system kinked 







Malfunction During prep, air was trapped in the hub Additional information will be 






Death During implant the coil did not detach, during 
withdrawal coil stretched and detached 





Malfunction Delivery system severed several centimeters 
from proximal hub connection, coil could not 
detach 
Additional information will be 
submitted within 30 days of receipt 
 
2/23/2012 
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Table 35.  Key Personnel - Roles and Responsibilities 
Contact Information Responsibilities 
Study Director, 
Veterinarian, VSAM Professor, 
Board Certified Cardiologist 
Texas A&M University 




Matthew W. Miller, DVM, DACVIM 
 
 
Overall responsibility for the technical conduct of the 
study, as well as for the interpretation, analysis, 
documentation and reporting of results and represents 
the single point of study control.  
Director, Texas A&M Institute 
for Preclinical Studies, 
Professor of Surgery, 
College Station, TX  77843 
979-847-8477 
tfossum@tamu.edu 







Texas A&M University 








Provide technical support to the Study Director as 
needed. 
Veterinarian 
Texas A&M University 




Cathy Ruoff, DVM 
 
Provide veterinary care to study animals, provide 
contributing scientist report for animal health.  Work 
with CMP Veterinarian and study director to monitor 
animal health and address all animal health issues. 
Veterinarian 
Texas A&M University 
Texas A&M Institute for 
Preclinical Studies 
vetjjg@gmail.com  
Lee Jae Guo, DVM 
 
 
Provide surgical and technical support to the Study 
Director. Work with the TIPS Veterinarian to 




Texas A&M University 
College of Veterinary Medicine 
Comparative Medicine Program 
979-845-7433 
elliottjj@tamu.edu  





Collaborate with TIPS veterinary staff to provide 
animal care and husbandry.  Oversees the 
Comparative Medicine Program (CMP). 




Contact Information Responsibilities 
Laboratory Manager 
Texas A&M University 






Manage anesthesia services, post-surgical care, and 
routine observations of study animals. Manage 
archives, and provide record quality control 
oversight, provide technical support, and assist with 
data collection as needed. 
Assistant Research Specialist 
Texas A&M University 







Provide anesthesia, post-op, animal health care, daily 
observations, surgical support, supervise veterinary 
technicians, assist with data collection. 
Senior Research Associate 
Texas A&M University 










Provide clinical pathology, laboratory testing, 
compile data, and provide data to the study director. 
Research Associate 
Texas A&M University 




Julie Grinde, BS 
 
Serve as lead study coordinator. Provide assistance to 
the Study Director and coordination of study 
activities, monitor animals, collect study data, 
compile study data, and assist in preparation of 
reports. 
Research Associate 
Texas A&M University 




Katy Bonugli BS, RVT, RDMS 
 
Provide assistance to the Study Director and 
coordination of study activities, monitor animals, 
collect study data, compile study data, and assist in 
preparation of reports. 
Associate Research Specialist 
Texas A&M University 
Texas A&M Institute for 
Preclinical Studies 
sbrownlee@tamu.edu  
Sheila Brownlee, CST/CFA 
 
Oversee operating room personnel, provide surgical 
assistance, assist in data collection and preparation of 
surgical reports. 
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Contact Information Responsibilities 
Pathologist, 
Texas A&M University 





Fred Clubb, DVM, PhD, DACLAM 
 
 
Lead pathologist, provide pathology services, 
perform gross necropsies, perform histological 
evaluations, and prepare a contributing scientist 
report. 
Pathologist, 
Texas A&M University 





Karen Trainor, DVM, MS, DACVP 
 
 
Provide pathology services, perform gross 
necropsies, perform histological evaluations, and 
assist in the preparation of a contributing scientist 
report. 
Pathologist 
Texas A&M University 










Provide pathology services, perform gross 
necropsies. 
Histology – Manager 
Cardiovascular Pathology 
Laboratory 
Texas Heart Institute 
832-355-2825 
ppotts@heart.thi.tmc.edu 




Provide management oversight for THI Pathology 
Lab services. 
Associate Lab Manager 
Texas A&M University 
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Table 36.  Testing Facility and Other Sites - Responsibilities 
Location Responsibilities 
Texas A&M Institute 
for Preclinical Studies 
(TIPS) 





Testing Facility  
Responsible for overall technical conduct of the study 
including, administration of test articles, animal acquisition, 
animal care and husbandry, veterinary care, clinical assessments 
and observations, clinical diagnostic testing, and preparing a 
comprehensive final report. 
Texas A&M 
University 









Responsible for gross necropsy, tissue harvest, microscopic 
analysis of target organs, and providing a contributing 
scientist’s report.  









Responsible for preparing tissue for light microscopy including 





















1. BACKGROUND OF THE DISEASE AND TREATMENT OPTIONS  
This protocol covers the animal studies under a National Institute of Health (NIH) 
grant titled “Shape Memory Polymers for Treating Stroke (R01EB000462)”.  The 
grant supports the research and development of technologies that may be able to 
improve the treatment and prevention of stroke.  Stroke is a major cause of mortality 
and the primary cause of long-term disability in the United States.  According to the 
National Stroke Association, approximately 732,000 Americans suffer a stroke each 
year of which 160,000 do not survive.  The American Heart Association estimates the 
total cost of stroke to the U.S. to be about $56 billion.  Of all strokes, approximately 
20% are hemorrhagic, 60% are large vessel occlusions, and 20% are due to small 
vessel disease, resulting in “lacunar” infarcts. 
 
2. OBJECTIVES 
The objectives of the study are: 
1) Test the applicability of a unique catheter-delivered device for management of 
experimentally induced vascular abnormalities with the intention of applying 
these devices to disease in human beings. 
 
2) Implement a mechanical thrombectomy device that will greatly improve the 
efficacy of removing clots, extend the window that the treatment can be 
implemented (from 5 to as long as 12 hours), and provide a treatment that does 
not have the bleeding risks of t-PA. 
 
3. REGULATORY COMPLIANCE 
A. GOOD LABORATORY PRACTICE  
Data from this study is not intended for submission to the United States Food and 
Drug Administration (FDA) to support safety. This study is not subject to and 
will not be conducted in accordance with the FDA, Good Laboratory Practices 
for Non-clinical Laboratory Studies, 21 CFR, Part 58.     
 
B. AMENDMENTS AND DEVIATIONS 
 
Changes to the study protocol will be issued in the form of amendments and will 
be approved by the Study Director, Sponsor Representative, and TIPS Testing 
Facility Management. Deviations from the study protocol will be documented as 
“Notes to Study” and will be authorized by the Study Director. Study 
amendments impacting approved procedures involving animals as described in 
the Animal Care and Use Protocol will be submitted to the Texas A&M 
Institutional Animal Care and Use Committee for review and approval prior to 
initiating a study protocol amendment. 
 




C. ANIMAL WELFARE 
 
Animals will receive humane care in compliance with the “Principles of 
Laboratory Animal Care,” formulated by the National Society for Medical 
Research, and the “Guide for the Care and Use of Laboratory Animals” (NIH 
Publication).  The Testing Facility and Testing site will conduct the study in 
accordance with the Animal and Plant Health Inspection Service, United States 
Department of Agriculture, Animal Welfare Act, 9 CFR, Parts 1, 2, and 3 as 
applicable; according to an Animal Use Protocol (AUP) approved by the 
University’s Institutional Animal Care and Use Committee (IACUC); and this 
Sponsor-approved “study” protocol.  TIPS is part of the TAMU USDA registered 
AAALAC accredited program and Public Health Service (PHS) assurance. As 
stated in section 3.B. study amendments impacting approved procedures 
involving animals as described in the Animal Care and Use Protocol will be 
submitted to the Texas A&M Institutional Animal Care and Use Committee for 
review and approval prior to initiating a change to the approved procedures. 
 
4. DATES 
Study Initiation Date – The date the protocol is signed by the Study Director. 
Study Completion Date – The date the final report is signed by the Study Director. 
 
5. STUDY DESIGN 
 
Animals will undergo anesthesia for aneurysm creation surgery.  Vascular 
abnormalities (saccular aneurysms) will be created in major blood vessels (carotid 
arteries) in pigs followed by treatment of the aneurysms with the test and control 
devices that will help support the diseased vessel, prevent vessel rupture and promote 
healing.  The devices will be deployed by either a catheter based technology through 
the femoral artery or by surgically placed devices directly into the created aneurysm 
using direct visualization.  The animals will undergo imaging studies (fluoroscopy, 
CT angiography (CTA), and/or MR angiography (MRA)).  The animals will be 
recovered and survived for their assigned time point.  At the end of the study the 
animals will again be anesthetized and will undergo imaging studies (fluoroscopy, 
CTA, and/or MRA).  The animal will then undergo testing of the thrombectomy 
device on clots placed in the branches of the external carotid artery, subclavian 
artery, and/or renal/mesenteric arteries.  The animals will be euthanized and carotid 










Table 37.  Description of Each Test Group Used in Animal Study 
Test Group Number of Animals Duration of Experiment 
I 14 pigs 30 days 
II 14 pigs 90 days 
 
 
6. STUDY DURATION 
The in-life phases of each animal in the study will be 30 days (± 2 days) or 90 days 
(± 3 days) depending on the assigned group. 
 
7. TEST SYSTEM 
 
Table 38.  Description of Animals Used in Animal Study 
Total Number:  28 
Species:  Swine 
Strain: Domestic cross (Yorkshire, Yorkshire-cross) 
Weight:  30 to 45 kg 
Age:  Mature 
Sex:  Either 
Source/Supplier:  TAMU or CMP approved vendor 
 
 
A. ANIMAL IDENTIFICATION 
 
The animals will be identified by an ear tag or tattoo (Standard Operating 
Procedure (SOP) CMP-02-002, Identification of Swine, Ovine, Caprine, Canine, 
Bovine).  All animal records and data sheets will contain the unique animal 
identification number. TIPS personnel will verify the animal’s number by 
checking the ear tag or tattoo prior to performing any procedures. A cage card 
containing a minimum of the animal’s number, name of Study Director, the 
Animal Use Protocol (AUP) number, and the Study Protocol number will be 
maintained on the cage and moved with the animal at all times. If animals have 
more than one identification number in their records, documentation will be 








B. ANIMAL HOUSING 
 
The animals will be individually housed indoors in aluminum pens (24 sq. ft. 
minimum) on raised slated flooring.  Optimal environmental conditions will 
target a range of 30-70% humidity and a target temperature range of 61⁰-81⁰ 
Fahrenheit.  The humidity and temperature may be observed outside of the target 
range during periods of cleaning.  A twelve (12) hour on / twelve (12) hour off 
light cycle will be maintained. Cages will be cleaned in the morning and, if they 
are soiled, in the afternoon. Cages will be disinfected at least weekly.   
 
C. FOOD AND WATER 
 
Animals will be fed a commercially available laboratory swine diet twice daily 
and will have free access to water filtered through reverse osmosis (SOP CMP-
02-006, Feeding and Watering GLP Research Animals).  The animals may be 
given treats as part of enrichment.  All treats will be recorded in the animal’s 
record.  There are no known contaminants in the food that will impact the study. 
Water analysis has been performed and there are no known contaminants in the 
water that will impact the study. 
 
D. ANIMAL HEALTH 
 
i) ACQUISITION – QUARANTINE 
(1) The animals will be received and quarantined at TIPS for a minimum of 
fourteen (14) days prior to study.  
(2) If animals require vaccination or deworming upon arrival to TIPS, 
quarantine may be extended an additional fourteen (14) to thirty (30) days 
from treatment at the discretion of a CMP Veterinarian.  
(3) Animals will be weighed upon arrival and a visual exam performed by a 
veterinarian.  Animals will be evaluated daily during quarantine for signs 
of illness by a veterinarian or a qualified animal health technician. 
(4) Daily observations, vaccinations, examinations, weights, treatments, and 
any diagnostic tests (hematology, serology, parasitology) will be 
documented in the animal’s records.   
(5) Animals may be conditioned to handling during the quarantine period and 
may be given small quantities of food treats approved by the Study 
Director and CMP Veterinarian.  All food treats will be recorded in the 
animal record. 
(6) At least three (3) days after arrival at TIPS and prior to release from 
quarantine, the animals will undergo a complete physical examination 
and blood collection. Jugular blood samples will be collected using an 
appropriately sized needle. Approximately 1-12cc of blood will be 




withdrawn and submitted for a complete blood count (CBC), coagulation 
analysis, and blood chemistry analysis (basic health screen) (see Section 
7).  The animals will be sedated with Telazol (5-10 mg/kg IM) for the 
blood collection.  
 
ii) RELEASE FROM QUARANTINE & STUDY ENROLLMENT 
Prior to study assignment and release from quarantine the animals will be in 
good health as determined by physical examination from a CMP veterinarian, 
assessment of hematology and blood chemistry parameters (see Section 11). 
 
iii) ANIMAL OBSERVATIONS AND VETERINARY CARE 
(1) After animal assignment to the study, daily health care will be provided 
by TIPS veterinary staff (veterinarians and trained veterinary technicians) 
in cooperation with a CMP Veterinarian. Animals observed to have any 
abnormal condition will be evaluated by veterinary staff and the findings 
will be documented. Any medications and treatment instructions will be 
documented in the animal’s record. 
(2) CMP animal care staff will record daily food intake, general condition as 
observed during routine husbandry, and presence/absence and 
consistency of stool.  Any abnormalities observed by animal care staff 
will be recorded in the animal’s record and promptly reported to a CMP 
Veterinarian who will assess the animal and notify the TIPS Veterinarian. 
The TIPS Veterinarian will notify the Study Director.  The CMP 
Veterinarian will make a reasonable attempt to reach the TIPS 
Veterinarian and/or Study Director when health problems arise.  In the 
event the TIPS Veterinarian or Study Director cannot be reached the 
CMP Veterinarian will decide the best method to resolve the health 
problem to prevent unnecessary pain and discomfort to the animal.  
 
NOTE: If necessitated by the animal’s health, more frequent or extended 
observations may occur at the discretion of the Study Director, TIPS 
Veterinarian, or CMP veterinarian in collaboration with the Study 
Director. 
 
E. MORIBUND ANIMALS 
 
Severe health problems (reasons for euthanasia) include moribund status, 
inability to get food and water, intractable pain, and major organ system 
dysfunction (as indicated by blood work).  If any of the preceding occurs and is 
not correctable by conventional veterinary therapy, and are deleterious to the 
animal and/or is intractable to treatment, the animal will be euthanized.  The 
animal may be sedated with Telazol (5-10 mg/kg IM) prior to euthanasia. 
 




The Study Director, TIPS Veterinarian, and CMP Veterinarian will cooperatively 
make decisions related to early sacrifice.  If possible, a final data collection will 
be performed prior to sacrifice.  
 
If an animal requires early euthanasia, every effort will be made to collect final 
data. The animals will be Heparinized and euthanized as described in Section 16.   
Animals that are euthanized early or expire unexpectedly will undergo a 
necropsy as described in Section 17 and the tissues listed in Section 18 will be 
harvested and archived.  Heparin (30,000 units) will be administered IV at least 5 
minutes prior to euthanasia. If the necropsy cannot be performed immediately the 
carcass will be stored in the necropsy cold room until the necropsy can be 
performed. 
 
8. EQUIPMENT AND COMPUTERIZED SYSTEMS 
The following is a list of equipment that may be used in this study and either 
generates, measures, or assesses data or has been deemed critical study equipment.  
 
TIPS Equipment and Computerized Systems 
Landmark Vetland EX3000 or VSA 2100 Veterinary Anesthetic Machine 
Hallowell EMC or SurgiVet VetPAC Ventilator 
Capnograph – Novametrix Tidal Wave Model # 615 
Pulse Oximeter – Nellcor Model # N65 or Model # NPB40 
Welch Allyn SureTempPlus Veterinary Thermometer  
Cardell MAX-12/MAX-12 DUO 
Floor Scale – GSE Model Digital Weigh Indicator/Rough Deck Floor Scale 
Abbott Cell-Dyn 3700 Hematology Analyzer 
Beckman Coulter Olympus AU400e Chemistry Analyzer 
Diagnostica Stago STA Compact Hemostasis Analyzer 
Microscope: Olympus BX51 
Orchard Harvest Laboratory Information System (LIS) 
Microsoft Office Excel Software 2007 and 2010 
Philips Allura Xper FD 20 C-arm System – Release 7.0.2 
Siemens Biograph mCT 
Siemens Magnetom Verio MRI 
Medrad Stellant CT Injector 
Medrad Spectris Solaris EP MR Injector 
Medrad Mark V Provis Power Injector 
 
CVP Equipment and Computerized Systems 
Microscope: Olympus BX41 
Spot 2 Mega Sample Digital Microscope Camera  
Balance: TP-12, 12000G/1G  
Balance: TP-1502, 1500G/0.01G  




Super Cool Scan 9000 (LS-9000) Film Scanner  
Eva-Dry EDV-2200 Electric Mid0Size Dehumidifier 
Microscope Camera: Nikon Digital Sight DS-Ri1 
Microscope Camera: Nikon Digital Sight Viewing Monitor 
Microscope: Olympus BX46F 
Apple Mac Pro #A1186 
Microsoft Office 2011 Mac – Microsoft Word and Microsoft Excel 
software version 12.2.5 
Mac Pro #A1186 
Adobe Photoshop CS4 software version 11.0.2 
Nikon Scan 4 version 4.0.0.3020 
Microsoft Office 2011 Mac – Microsoft Word and Microsoft Excel 
Software version 12.2.6 
Dell Computer OXPCG3 
Microsoft Office 2010 – Microsoft Word and Microsoft Excel Software 
version 14.0.6029.1000 
Dell OptiPlex 990 Small Form Computer 
Microsoft Office 2010 – Microsoft Word and Microsoft Excel software 
version 14.0.6029.1000 
Digital Camera Firmware DS-L2 
 
Note: Texas Heart Institute is responsible for maintaining an equipment 
inventory list.  
 
9. EQUIPMENT AND DEVICES 
A. QUANTITY – DEVICES  
 
Table 39.  Test and Control Article Quantities 
Quantity Item 
28 Test Devices – Shape Memory Polymer devices (one per aneurysm) 
112 




B. TEST ARTICLE 
 
Shape Memory Polymer (SMP) Foam is a unique catheter delivered device for 
management of vascular abnormalities.  If the delivery method has not been 
developed, then the SMP may be directly placed into the aneurysm prior to the 
aneurysms’ domes being closed. 
 
 




C. TEST ARTICLE LABELING 
 
The sterilization date will be labeled on each container/package of all devices 
that are to be implanted. 
 
D. CONTROL ARTICLE AND ANCILLARY EQUIPMENT LABELING 
 
The model number, serial number, expiration date, and storage requirements will 
be labeled on each container/package of all devices that are to be implanted or 
used to assist with the implantation procedure (e.g. introducers, guide catheters, 
guide wires). 
 
E. EQUIPMENT AND DEVICE SHIPPING/RECEIVING/DISPOSITION 
 
i) Equipment and devices will be shipped or delivered to the testing facility by 
commercial carrier or hand carried.  If shipped the Sponsor will notify TIPS 
of the shipment and expected arrival date.  A TIPS Chain of Custody form 
will accompany each shipment. 
 
ii) Upon receipt all contents will be inspected and the Chain of Custody form 
will be completed, retained in the study records, and a copy will be submitted 
to the Sponsor.  
 
iii) In the event that any equipment or device containers are damaged the 
Sponsor will be notified and the damaged articles will be retained pending 
instructions from the Sponsor.   
 
iv) An inventory will be maintained of equipment and device receipt, 
administration, and disposition.   
 
v) TIPS will return equipment and unused devices to the Sponsor at the end of 
the study and will reconcile the inventory list.  
 
F. EQUIPMENT AND DEVICE STORAGE CONDITIONS 
 
The Sponsor will provide the equipment and devices as listed in Table 1.  The 
devices to be implanted will be in sterile form ready for implantation in sufficient 
number including backup for all proposed experimentation.  All accessories and 
supplies intended to come in contact with the sterile field will be sterile.  The 








10. METHODS FOR CONTROL OF BIAS 
Blinding of study personnel or the pathologist is not required. 
 
11. CLINICAL PATHOLOGY 
A. An appropriate sized needle and syringe will be used to enter the left or right 
jugular or pre-caval vein for blood collection.  Approximately 1-12 cc of blood 
will be withdrawn for complete blood count (CBC), coagulation analysis, and 
chemistry analysis (basic health screen) during the quarantine period, at time of 
implant, and prior to euthanasia. The assays to be performed are listed in 
Appendix A. 
 
B. Additional blood samples may be collected and submitted for analysis if deemed 
necessary for clinical evaluation of study animals at the discretion of the Study 




Aspirin (3-5 mg/kg PO) and Clopidogrel (Plavix) (5-10 mg/kg PO) will be given 
once daily beginning two days prior to surgery. Animals will be weighed within 
seventy-two (72) hours prior to anesthesia induction.  Animals will be fasted 
from food and treats twelve (12) hours prior to anesthetic and sedation 
procedures.  Water will be provided ad lib.   
 
B. ANESTHESIA INDUCTION/MAINTENANCE 
Pigs will be pre-medicated with Telazol at 5 mg/kg and Buprenorphine at 0.01-
0.05 mg/kg intramuscularly (IM) prior to induction. Anesthesia will be induced 
with Isoflurane (~3-4%) in Oxygen.   
 
The swine’s heart rate and pulse quality, respiratory rate and character, and 
temperature will be evaluated and recorded at induction. In the event that 
abnormalities are noted the Study Director will be contacted before proceeding.  
 
Using aseptic technique, an appropriately-sized (~18-20g) catheter will be 
placed, a T-port attached, and catheter secured in the auricular vein of either ear 
for venous access. An appropriately-sized endotracheal tube will be placed, 
secured in place, and the cuff inflated. The capnograph will be connected 
between the endotracheal tube and the breathing circuit. A pulse oximetry probe 
will be attached to the tongue or other appropriate location for monitoring.  
 




Anesthesia will be maintained with Isoflurane (0.5-4%) in 100% Oxygen. The 
animal will be connected to the ventilator and mechanical respiration will be 
provided at a rate of 6-12 BPM and a tidal volume of 10-20 mL/kg. 
 
Lactated Ringers solution will be given IV at a rate of 10-20 mL/kg/hr.  Draxxin 
(2.5 mg/kg IM) will be given. 
Areas for electrocardiogram (ECG) lead placement and for electrocautery ground 
plate will be shaved (if needed). The area over both of the jugular veins and 
femoral veins will be shaved and cleaned.   
C. SURGICAL PREPARATION 
 
The animal will be transported to the surgical suite, transferred to the operating 
table, and placed/secured in dorsal recumbency.  ECG electrodes will be placed 
and ECG cables connected, and a rectal or oral temperature probe will be placed. 
The Bair Hugger blanket will be placed and connected to the Bair Hugger unit to 
provide thermal support if needed.  
The surgical sites over the neck and groin will be prepared using aseptic 





An incision made on and/or immediately adjacent the midline of the neck.  After 
reflecting the cervical musculature, an approximately 4 cm long segment of the 
external jugular vein will be isolated and excised after a 2-0 silk ligature is 
placed at each end of the segment.  This segment of the vein will then be divided 
transversely, yielding two open ended pouches.  The carotid arteries will then be 
sequentially exposed and cleaned of adventitia.  Systemic anticoagulation 
(Heparin 200-300 IU/kg IV) will be administered to maintain activated clotting 
times of 1.5-3 times baseline in order to prevent thromboembolic complications 
related to the procedure itself.  Vascular clamps will be placed at each end of the 
area of interest on the artery to provide temporary vessel occlusion.  
Nitroglycerin will be directly applied to the exposed artery as needed to dilate 
and/or counteract constriction of the vessel.  An approximately 7mm arteriotomy 
will then be made, and end-to-side anastomosis of the venous pouch to the 
carotid artery will be performed using an appropriate sized suture.  In this 
fashion, an aneurysm measuring 5-15 mm in diameter will be created on each 
carotid artery. 
 
Treatment will be performed soon after creation of the aneurysms, as these 
aneurysms may spontaneously thrombose over time.  Angiography will be 
performed after surgical preparation of the femoral areas followed by a trans-
femoral access technique of accessing the artery either percutaneous or via direct 




arterial cut down for placement of an introducer sheath.  Following carotid 
angiography and assessment of patency of the aneurysm, the shape memory 
polymer (SMP) foam device will be implanted in one of two manners: catheter 
based deployment or directly placed in the aneurysm.  A catheter will be 
advanced under continuous fluoroscopic guidance through a guiding catheter (4-
8 Fr), position confirmed, and the device deployed.  Direct placement of the SMP 
foam device will be performed by having the surgeon place the device directly 
into the created aneurysm just before the sac is sutured closed.  Digital 
subtraction and 3-D Angiography will be performed post SMP foam placement 
to document parent vessel integrity and assess aneurysm filling.  After integrity 
and filling have been assessed, the incision(s) will be closed.  A MRA may be 
performed. 
 
E. ANESTHESIA RECOVERY  
 
The Isoflurane will be discontinued, and the subject will be weaned from oxygen.  
The animal will be placed on room air until the animal is showing signs of 
recovery (palpebral reflex, swallowing, and presence of jaw tone).  At this point 
the animal will be extubated.  Buprenorphine (0.01-0.05 mg/kg IM) may be 
repeated every 6-8 hours as needed for analgesia.  Animals will be returned to 
standard animal housing only after they are fully ambulatory and have no ataxia.  
 
F. POST SURGICAL PERIOD 
 
The animals will be closely monitored several times during the day by technical 
and veterinary staff for a minimum of the first 1-3 postoperative days (24-72 
hours).  Once the animal is deemed healthy and hemodynamically stable by 
veterinary staff, daily observations will be performed at least two (2) times daily 
for the duration of the study by TIPS veterinary technical staff (veterinarian or 
trained veterinary technician).  Depending upon the animal’s condition, more 
frequent monitoring will be instituted.  Aspirin (3-5 mg/kg PO) and Clopidogrel 
(Plavix) (5-10 mg/kg PO) will be given once daily every 24 hours until 
euthanasia. 
 
13. FOLLOW-UP DATA COLLECTION PROCEDURES 
At the completion of the observation period for each group, the study subjects will 
again be anesthetized using the previously described protocol.  Angiography will be 
performed via the trans-femoral technique accessing the artery either percutaneously 
or via direct arterial cut down.  Angiography will be performed to more completely 
characterize chronic changes in aneurysm filling, including aneurysm exclusion, 
intraluminal thrombus formation, or distal emboli.  These study subjects may have 
MRA or CTA performed in addition to standard digital subtraction and 3-D 




angiography to more completely characterize the SMP foam implant.  After final 
angiographic evaluation of the aneurysms but prior to euthanizing the study subject, 
the animal will undergo thrombectomy device evaluation. 
 
14. THROMBECTOMY DEVICE EVALUATION 
The guiding catheter will be placed into branches of the external carotid artery, 
subclavian artery, and/or renal/mesenteric arteries.  Baseline angiography will be 
performed.  Vessels measuring 2-6 mm in diameter will be targeted, as this is the 
size of the major intracranial arteries affected clinically by thromboembolic stroke.  
Autologous blood clot will be prepared from blood withdrawn from the animal 
immediately after induction of anesthesia.  This will be allowed to stand in a syringe 
in order to allow clot to form.  Differing consistencies of clot will be created, ranging 
from acute thrombus with a more jelly-like consistency to denser clot created using 
thermocoagulation or addition of thrombin.  An amount of clot will then be selected, 
with the size based upon the diameter of the branch vessels visualized 
angiographically.  The clot will then be measured and photographed for comparison 
against the amount of retrieved clot, if any, and injected through the catheter.  The 
animal will be heparinized to prevent in situ thrombus formulation during occlusion 
by the injected clot.  Degree of arterial occlusion will be assessed angiographically 
using a standard grading scale, ranging from normal flow to complete occlusion.  
Under fluoroscopic guidance, the SMP thrombectomy devices will then be advanced 
through the guiding catheter, and attempts at clot extraction will be made.  After 
these attempts, angiography will again be performed to determine degree of 
recanalization, if any, and to evaluate for any evidence of device-related arterial 
injury.  Number of attempts, technical factors related to device deployment (e.g., 
ability to reach desired location, passage through and beyond clot, success of 
actuation, time to actuation, etc.), degree of recanalization, amount of clot removed, 
and any evidence of arterial injury will be recorded.  For each animal, attempts will 
be made in multiple different vessels in order to maximize the number of devices 
that can be tested, so long as the animal remains hemodynamically stable and can 
continue to be maintained under anesthesia. 
 
15. EUTHANASIA 
If the test subject becomes physically compromised as described in Section 7 E, and 
the condition is deleterious to the animal and/or is intractable to treatment, the 
animal will be euthanized. 
Following the final data collection, the animals will remain anesthetized and will be 
given 30,000 units of Heparin IV.  The Heparin will be given at least 5 minutes prior 
to euthanasia to allow adequate time to circulate.  The animal will then be euthanized 
with a barbiturate derivative (80-120 mg/kg), administered intravenously. 
After euthanasia the following criteria will be used to confirm that the animal is 
deceased: absence of all ocular reflexes, lack of audible breath and heart sounds for 




longer than five minutes (via stethoscope) and lack of cardiac electrical activity 
(when applicable) for longer than five minutes. 
 
16. NECROPSY 
A gross necropsy with photography will be performed for all animals.  The identity 
of the animal will be verified.  The skin and body surfaces will be examined and any 
observations will be recorded on the necropsy form.  Photographs will be taken of 
any abnormalities.  The internal organs will be examined and any abnormalities will 
be noted and photographed.  
The carotid arteries and other vessels of interest will be perfusion fixed per SOP 
CVP-07-013, Perfusion Fixation of Tissue during Necropsy, using saline and 
formalin. Briefly, the vasculature will be retrograde and antegrade perfused with 
phosphate buffered saline followed by formalin until the tissues begin to be fixed. 
17. HISTOPATHOLOGY 
The carotid arteries (with aneurysms) and the targeted vessels from all animals will 
be preserved and sent to the College of Veterinary Medicine Cardiovascular 
Pathology Laboratory (TAMU-CVP) for a histopathology evaluation.  
The intact, perfused, formalin-fixed aneurysms will be examined and subsequently 
photographed.  Once the quality of the gross photographs is confirmed, the 
aneurysms will be placed in plastic.  Sections will be taken perpendicular to the long 
axis of the carotid vessel.  The sections will be stained with Hematoxylin and Eosin 
(H&E) and Trichrome.  Any remaining tissue will be stored as plastic blocks. 
The intact, perfused, formalin-fixed vessels will be examined and subsequently 
photographed.  Once the quality of the gross photographs is confirmed, the targeted 
vessels will be placed in cassettes and sent to THI.  The tissue blocks will be placed 
in paraffin.  Sections will be taken perpendicular with the long axis of the 
vessel.  The sections will be stained with Hematoxylin and Eosin (H&E) and 
Trichrome.  Any remaining tissue will be stored as paraffin blocks.  
The histopathological results from the pathologists will consist of a descriptive 
narrative for the gross tissue and the microscopic results.  Analysis will be performed 
from histological examination of the aneurysm sac, the carotid arteries adjacent to 
the aneurysms, and the targeted vessels.  The tissue from each of the groups will be 
compared using the following factors: degree of inflammation, fibrosis, and tissue 
damage.  The extent and severity of damage will be compared within the group.  
Microscopic images will be captured per SOP CVP-07-21 and CVP-07-043.  
Representative images of the stained sections will be included in the pathology 
report. 




Organs with gross lesions will be examined microscopically and findings reported.  
18. DATA ANALYSIS AND REPORTING 
All study data will be analyzed by the Study Director and a final report will be 
prepared and submitted to the Sponsor within 90 calendar days after receipt of the all 
of the data including the pathology report.   
A Contributing Scientists’ report will be included from the pathology group.  The 
final report will describe the roles and responsibilities of each of the pathologists.  
The final study report will include tables of data and analysis of the following: 
 Survival and Disposition 
 Clinical Findings: Total Occurrence/No. of Animals 
 Animal sequence 
 Sex, Body Weights, Age 
 Hematology Values 
 Serum Chemistry Values 
 Scheduled and Unscheduled Necropsies 
 Macroscopic Findings 
 Microscopic Findings 
19. RECORDS MANAGEMENT 
All study related raw data generated by TIPS will be kept at TIPS in the archive until 
the signing of the final report.  
Records to be maintained will include but not be limited to the following: 
 Signed protocol 
 Surgical reports 
 Test article and ancillary equipment chain of custody 
 Data sheets 
 Animal health records 
 USDA records (receiving records, examinations, clinical diagnostic 
testing, daily observations) 
 Clinical pathology data 
 Final report 
 Amendments and Deviations 
 Notes to study file 
 Contributing scientists’ reports (pathology) 
 Necropsy photos* 
 Tissue blocks* 




 Tissue slides* 
* Pathology related items will be kept at CVP until the pathology report is 
signed.  The items will then be transferred to TIPS. 
Copies of all study raw data and study related records will be collected and retained 
in the TIPS archive for a period of five (5) year from the date the final report is 
signed by the study director.  Original paperwork will be provided to the Sponsor.  
TIPS will retain an exact copy of the final report. The Sponsor will be provided with 
the original of the final report. At the end of five (5) years the Sponsor will be 
notified of the intent to dispose of the records and given the option of disposal, 
extended storage, or the records can be shipped to the Sponsor.  Final disposition of 
the records will be documented in the TIPS archive with the final report. 







Assay Complete Blood Count (CBC) 
Components 
Leukocyte count (WBC) 
Automated and manual WBC 
differentials 
Erythrocyte count (RBC) Hemoglobin (HGB) 
Hematocrit (HCT) Mean corpuscular HGB (MCH) 
Mean corpuscular volume (MCV) 
Mean corpuscular HGB 
concentration (MCHC) 
RBC distribution width (RDW) Platelet count (PLT) 
Mean Platelet Volume (MPV)  




Specimen Storage 2-8°C if same day testing not possible 
 
ii) Chemistry 
Assay Chemistry Panel (Chem) 
Components 
Albumin ALT (alanine aminotransferase) 
AST (aspartate aminotransferase) BUN (blood urea nitrogen) 
Calcium (Ca) Creatinine 





Total bilirubin Total Protein 
Specimen Type Serum (yellow top serum separator tube) 
Specimen 
Processing 
Centrifuge and aliquot serum 
Specimen Storage 2-8°C if same day testing not possible 
 iii)  Coagulation 
Assay Coagulation Panel 
Components 
PT – prothrombin time Fibrinogen 
APTT – activated partial thromboplastin time  
Specimen Type Sodium citrate plasma (blue top tube) 
Specimen 
Processing 
Centrifuge and aliquot plasma 
Specimen Storage -80°C if same day testing not possible 




APPENDIX D  
 
FOAM ACTIVITY DIAGRAMS 
 
 






















Figure 14. Activity Diagram for Etching and Cleaning the SMP Foam 
